{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:47:09Z","timestamp":1794847629870,"version":"4.9.1"},"publisher-location":"Cham","reference-count":353,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032121653","type":"print"},{"value":"9783032121660","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-12166-0_14","type":"book-chapter","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:16:52Z","timestamp":1783768612000},"page":"401-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges"],"prefix":"10.1007","author":[{"given":"Catarina","family":"Freitas-Dias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"14_CR1","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.7314\/APJCP.2015.16.16.6947","volume":"16","author":"MM Abbasi","year":"2015","unstructured":"Abbasi MM, Mehdipour M, Monfaredan A, Jahanban-Esfahlan R (2015) Hesa\u2014a down-regulates erb\/b2 oncogene expression and improves outcome of oral carcinoma in a rat model. Asian Pac J Cancer Prevent 16:6947\u20136951. https:\/\/doi.org\/10.7314\/APJCP.2015.16.16.6947","journal-title":"Asian Pac J Cancer Prevent"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.celrep.2018.08.015","volume":"24","author":"D Ackerman","year":"2018","unstructured":"Ackerman D, Tumanov S, Qiu B et al (2018) Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep 24:2596\u20132605. e5. https:\/\/doi.org\/10.1016\/j.celrep.2018.08.015","journal-title":"Cell Rep"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"e1S","DOI":"10.1378\/chest.12-2345","volume":"143","author":"AJ Alberg","year":"2013","unstructured":"Alberg AJ, Brock MV, Ford JG et al (2013) Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e1S\u2013e29S. https:\/\/doi.org\/10.1378\/chest.12-2345","journal-title":"Chest"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","volume":"198","author":"M Alexander","year":"2020","unstructured":"Alexander M, Kim SY, Cheng H (2020) Update 2020: management of non-small cell lung cancer. Lung 198:897\u2013907. https:\/\/doi.org\/10.1007\/s00408-020-00407-5","journal-title":"Lung"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"e50635","DOI":"10.15252\/embr.202050635","volume":"21","author":"P Altea-Manzano","year":"2020","unstructured":"Altea-Manzano P, Cuadros AM, Broadfield LA, Fendt S (2020) Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take. EMBO Rep 21:e50635. https:\/\/doi.org\/10.15252\/embr.202050635","journal-title":"EMBO Rep"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30:R921\u2013R925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081","journal-title":"Curr Biol"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","volume":"20","author":"SJ Antonia","year":"2019","unstructured":"Antonia SJ, Borghaei H, Ramalingam SS et al (2019) Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 20:1395\u20131408. https:\/\/doi.org\/10.1016\/S1470-2045(19)30407-3","journal-title":"Lancet Oncol"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","volume":"34","author":"MM Awad","year":"2016","unstructured":"Awad MM, Oxnard GR, Jackman DM et al (2016) MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent METgenomic amplification and c-Met overexpression. J Clin Oncol 34:721\u2013730. https:\/\/doi.org\/10.1200\/JCO.2015.63.4600","journal-title":"J Clin Oncol"},{"key":"14_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3978\/j.issn.2218-6751.2012.09.08","volume":"1","author":"F Aziz","year":"2012","unstructured":"Aziz F (2012) Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a concise review. Transl Lung Cancer Res 1:208\u2013213. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2012.09.08","journal-title":"Transl Lung Cancer Res"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/S12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban R, Roshangar L, Jahanban-Esfahlan R et al (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 18:59. https:\/\/doi.org\/10.1186\/S12964-020-0530-4","journal-title":"Cell Commun Signal"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.52547\/RBMB.10.2.327","volume":"10","author":"N Bakhtiyari","year":"2021","unstructured":"Bakhtiyari N, Sharifi A, Aftabi Y et al (2021) Association between NOX4 and Nrf2 genes in non-small-cell lung carcinoma: a case-control study. Rep Biochem Mol Biol 10:327\u2013333. https:\/\/doi.org\/10.52547\/RBMB.10.2.327","journal-title":"Rep Biochem Mol Biol"},{"key":"14_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-022-31963-4","volume":"13","author":"C Bartolacci","year":"2022","unstructured":"Bartolacci C, Andreani C, Vale G et al (2022) Targeting de novo lipogenesis and the lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun 13: 4327. https:\/\/doi.org\/10.1038\/S41467-022-31963-4","journal-title":"Nat Commun"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ccell.2016.06.022","volume":"30","author":"AH Berger","year":"2016","unstructured":"Berger AH, Brooks AN, Wu X et al (2016) High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 30:214\u2013228. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.022","journal-title":"Cancer Cell"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SHI et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863\u2013870. https:\/\/doi.org\/10.1200\/JCO.2011.35.6345","journal-title":"J Clin Oncol"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1158\/1535-7163.MCT-13-1091","volume":"13","author":"BM Bola","year":"2014","unstructured":"Bola BM, Chadwick AL, Michopoulos F et al (2014) Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther 13:2805\u20132816. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-1091","journal-title":"Mol Cancer Ther"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2006.10.020","volume":"11","author":"S Bonnet","year":"2007","unstructured":"Bonnet S, Archer SL, Allalunis-Turner J et al (2007) A Mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37\u201351. https:\/\/doi.org\/10.1016\/j.ccr.2006.10.020","journal-title":"Cancer Cell"},{"key":"14_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/09553002.2018.1558299","volume":"95","author":"G Boysen","year":"2019","unstructured":"Boysen G, Jamshidi-Parsian A, Davis MA et al (2019) Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. Int J Radiat Biol 95:436\u2013442. https:\/\/doi.org\/10.1080\/09553002.2018.1558299","journal-title":"Int J Radiat Biol"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"107451","DOI":"10.1016\/J.PHARMTHERA.2019.107451","volume":"206","author":"TP Brown","year":"2020","unstructured":"Brown TP, Ganapathy V (2020) Lactate\/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther 206:107451. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2019.107451","journal-title":"Pharmacol Ther"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"S718","DOI":"10.21037\/TCR.2018.06.09","volume":"7","author":"A Brunel","year":"2018","unstructured":"Brunel A, Samain R, Neuzillet C, Bousquet C (2018) Identification of two cancer-associated fibroblast markers revealing stromal heterogeneity in sustaining cancer progression and chemoresistance. Transl Cancer Res 7:S718\u2013S721. https:\/\/doi.org\/10.21037\/TCR.2018.06.09","journal-title":"Transl Cancer Res"},{"key":"14_CR23","doi-asserted-by":"publisher","unstructured":"Buescher JM, Antoniewicz MR, Boros LG et al (2015) A roadmap for interpreting 13 C metabolite labeling patterns from cells. Curr Opin Biotechnol 34:189\u2013201. https:\/\/doi.org\/10.1016\/j.copbio.2015.02.003","DOI":"10.1016\/j.copbio.2015.02.003"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2020.10.015","volume":"80","author":"JK Byun","year":"2020","unstructured":"Byun JK, Park M, Lee S et al (2020) Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity. Mol Cell 80:606. https:\/\/doi.org\/10.1016\/j.molcel.2020.10.015","journal-title":"Mol Cell"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","volume":"11","author":"RA Cairns","year":"2011","unstructured":"Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85\u201395. https:\/\/doi.org\/10.1038\/nrc2981","journal-title":"Nat Rev Cancer"},{"key":"14_CR26","first-page":"536","volume":"52","author":"V Calabr\u00f2","year":"1993","unstructured":"Calabr\u00f2 V, Mason PJ, Filosa S et al (1993) Genetic heterogeneity of glucose-6-phosphate dehydrogenase deficiency revealed by single-strand conformation and sequence analysis. Am J Hum Genet 52:536","journal-title":"Am J Hum Genet"},{"key":"14_CR27","unstructured":"Calithera Biosciences I (2022) Study Details | NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT02071862. Accessed 4 Sep 2025"},{"key":"14_CR28","doi-asserted-by":"publisher","first-page":"105123","DOI":"10.1016\/J.ESMOOP.2025.105123","volume":"10","author":"DP Carbone","year":"2025","unstructured":"Carbone DP, Ciuleanu TE, Cobo M et al (2025) Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA. ESMO Open 10:105123. https:\/\/doi.org\/10.1016\/J.ESMOOP.2025.105123.","journal-title":"ESMO Open"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1073\/pnas.1700600114","volume":"114","author":"C Carmona-Fontaine","year":"2017","unstructured":"Carmona-Fontaine C, Deforet M, Akkari L et al (2017) Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci USA 114:2934\u20132939. https:\/\/doi.org\/10.1073\/pnas.1700600114","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.18632\/ONCOTARGET.714","volume":"3","author":"O Catalina-Rodriguez","year":"2012","unstructured":"Catalina-Rodriguez O, Kolukula VK, Tomita Y et al (2012) The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget 3:1235. https:\/\/doi.org\/10.18632\/ONCOTARGET.714","journal-title":"Oncotarget"},{"key":"14_CR31","doi-asserted-by":"publisher","first-page":"30102","DOI":"10.18632\/ONCOTARGET.4945","volume":"6","author":"D Catanzaro","year":"2015","unstructured":"Catanzaro D, Gaude E, Orso G et al (2015) Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death. Oncotarget 6:30102. https:\/\/doi.org\/10.18632\/ONCOTARGET.4945","journal-title":"Oncotarget"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ajhp\/59.7.611","volume":"59","author":"RJ Cersosimo","year":"2002","unstructured":"Cersosimo RJ (2002) Lung cancer: a review. Am J Health Syst Pharm 59:611\u2013642. https:\/\/doi.org\/10.1093\/ajhp\/59.7.611","journal-title":"Am J Health Syst Pharm"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/J.MOLCEL.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW et al (2019) Mechanisms controlling PD-L1 expression in cancer. Mol Cell 76:359\u2013370. https:\/\/doi.org\/10.1016\/J.MOLCEL.2019.09.030","journal-title":"Mol Cell"},{"key":"14_CR34","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.18632\/AGING.204687","volume":"15","author":"QH Chang","year":"2023","unstructured":"Chang QH, Zhang YC, Zhang DY et al (2023) A novel methionine metabolism-related signature predicts prognosis and immunotherapy response in lung adenocarcinoma. Aging 15:3523. https:\/\/doi.org\/10.18632\/AGING.204687","journal-title":"Aging"},{"key":"14_CR3401","doi-asserted-by":"publisher","unstructured":"Chen G, Bao B, Cheng Y, Tian M, Song J, Zheng L, Tong Q (2023) Acetyl-CoA metabolism as a therapeutic target for cancer. Biomed Pharmacother 168:115741. https:\/\/doi.org\/10.1016\/j.biopha.2023.115741. ISSN 0753-3322","DOI":"10.1016\/j.biopha.2023.115741"},{"key":"14_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.2174\/1389557516666160609085520","volume":"16","author":"J Chen","year":"2016","unstructured":"Chen J, Yang J, Cao P (2016) The evolving landscape in the development of isocitrate dehydrogenase mutant inhibitors. Mini-Rev Med Chem 16:1344\u20131358. https:\/\/doi.org\/10.2174\/1389557516666160609085520","journal-title":"Mini-Rev Med Chem"},{"key":"14_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-022-00406-1","volume":"8","author":"J Chen","year":"2022","unstructured":"Chen J, Zou L, Lu G et al (2022a) PFKP alleviates glucose starvation-induced metabolic stress in lung cancer cells via AMPK-ACC2 dependent fatty acid oxidation. Cell Discov 8:1\u201316. https:\/\/doi.org\/10.1038\/s41421-022-00406-1","journal-title":"Cell Discov"},{"key":"14_CR37","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1002\/CAM4.4764","volume":"11","author":"S Chen","year":"2022","unstructured":"Chen S, Zhu H, Jin M et al (2022b) Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies. Cancer Med 11:4122\u20134133. https:\/\/doi.org\/10.1002\/CAM4.4764","journal-title":"Cancer Med"},{"key":"14_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10020-023-00763-x","volume":"30","author":"J Chen","year":"2024","unstructured":"Chen J, Zhao R, Wang Y et al (2024a) G protein-coupled estrogen receptor activates PI3K\/AKT\/mTOR signaling to suppress ferroptosis via SREBP1\/SCD1-mediated lipogenesis. Mol Med 30:1\u201317. https:\/\/doi.org\/10.1186\/s10020-023-00763-x","journal-title":"Mol Med"},{"key":"14_CR39","doi-asserted-by":"publisher","first-page":"e008811","DOI":"10.1136\/JITC-2024-008811","volume":"12","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhou Y, Ren R et al (2024b) Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma. J Immunother Cancer 12:e008811. https:\/\/doi.org\/10.1136\/JITC-2024-008811","journal-title":"J Immunother Cancer"},{"issue":"1","key":"14_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y (2024) Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol 17(1):1\u201324. https:\/\/doi.org\/10.1186\/S13045-024-01581-2","journal-title":"J Hematol Oncol"},{"key":"14_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4062\/BIOMOLTHER.2017.179","volume":"26","author":"ES Cho","year":"2017","unstructured":"Cho ES, Cha YH, Kim HS et al (2017) The pentose phosphate pathway as a potential target for cancer therapy. Biomol Ther (Seoul) 26:38. https:\/\/doi.org\/10.4062\/BIOMOLTHER.2017.179","journal-title":"Biomol Ther (Seoul)"},{"key":"14_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4062\/BIOMOLTHER.2017.178","volume":"26","author":"YK Choi","year":"2017","unstructured":"Choi YK, Park KG (2017) Targeting glutamine metabolism for cancer treatment. Biomol Ther (Seoul) 26:28. https:\/\/doi.org\/10.4062\/BIOMOLTHER.2017.178","journal-title":"Biomol Ther (Seoul)"},{"key":"14_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1535-7163.MCT-07-0482","volume":"7","author":"B Clem","year":"2008","unstructured":"Clem B, Telang S, Clem A et al (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 7:110\u2013120. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0482","journal-title":"Mol Cancer Ther"},{"key":"14_CR44","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"EA Collisson","year":"2014","unstructured":"Collisson EA, Campbell JD, Brooks AN et al (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543\u2013550. https:\/\/doi.org\/10.1038\/nature13385","journal-title":"Nature"},{"key":"14_CR45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/EMBOJ.2010.330","volume":"30","author":"C Cosentino","year":"2010","unstructured":"Cosentino C, Grieco D, Costanzo V (2010) ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 30:555. https:\/\/doi.org\/10.1038\/EMBOJ.2010.330","journal-title":"EMBO J"},{"key":"14_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/J.FREERADBIOMED.2018.10.450","volume":"130","author":"A Cruz-Berm\u00fadez","year":"2019","unstructured":"Cruz-Berm\u00fadez A, Laza-Briviesca R, Vicente-Blanco RJ et al (2019) Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-\u03b2 signaling. Free Radic Biol Med 130:163\u2013173. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2018.10.450","journal-title":"Free Radic Biol Med"},{"key":"14_CR47","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/JNCI\/DJR325","volume":"103","author":"WJ Curran","year":"2011","unstructured":"Curran WJ, Paulus R, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452\u20131460. https:\/\/doi.org\/10.1093\/JNCI\/DJR325","journal-title":"J Natl Cancer Inst"},{"key":"14_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/J.EJCA.2021.03.020","volume":"150","author":"FG Dall\u2019Olio","year":"2021","unstructured":"Dall\u2019Olio FG, Calabr\u00f2 D, Conci N et al (2021) Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. Eur J Cancer 150:99\u2013107. https:\/\/doi.org\/10.1016\/J.EJCA.2021.03.020","journal-title":"Eur J Cancer"},{"key":"14_CR49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2016.01.007","volume":"23","author":"SM Davidson","year":"2016","unstructured":"Davidson SM, Papagiannakopoulos T, Olenchock BA et al (2016) Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab 23:517\u2013528. https:\/\/doi.org\/10.1016\/j.cmet.2016.01.007","journal-title":"Cell Metab"},{"key":"14_CR50","doi-asserted-by":"publisher","first-page":"28339","DOI":"10.18632\/ONCOTARGET.8631","volume":"7","author":"BG Debeb","year":"2016","unstructured":"Debeb BG, Lacerda L, Larson R et al (2016) Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget 7:28339. https:\/\/doi.org\/10.18632\/ONCOTARGET.8631","journal-title":"Oncotarget"},{"key":"14_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/S42255-020-0172-2","volume":"2","author":"RJ DeBerardinis","year":"2020","unstructured":"DeBerardinis RJ, Chandel NS (2020) We need to talk about the Warburg effect. Nat Metab 2:127\u2013129. https:\/\/doi.org\/10.1038\/S42255-020-0172-2","journal-title":"Nat Metab"},{"key":"14_CR52","first-page":"66","volume":"146","author":"A Desmoulire","year":"1995","unstructured":"Desmoulire A, Redard M, Darby I, Gabbiani G (1995) Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 146:66","journal-title":"Am J Pathol"},{"key":"14_CR53","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1056\/NEJM199010043231403","volume":"323","author":"RO Dillman","year":"1990","unstructured":"Dillman RO, Seagren SL, Propert KJ et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940\u2013945. https:\/\/doi.org\/10.1056\/NEJM199010043231403","journal-title":"N Engl J Med"},{"key":"14_CR54","doi-asserted-by":"publisher","first-page":"906494","DOI":"10.3389\/FONC.2022.906494\/FULL","volume":"12","author":"M Domingo-Vidal","year":"2022","unstructured":"Domingo-Vidal M, Whitaker-Menezes D, Mollaee M et al (2022) Monocarboxylate transporter 4 in cancer-associated fibroblasts is a driver of aggressiveness in aerodigestive tract cancers. Front Oncol 12:906494. https:\/\/doi.org\/10.3389\/FONC.2022.906494\/FULL","journal-title":"Front Oncol"},{"issue":"8","key":"14_CR55","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ncb2789","volume":"15","author":"W Du","year":"2013","unstructured":"Du W, Jiang P, Mancuso A et al (2013) TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nature Cell Biol 15(8):991\u20131000. https:\/\/doi.org\/10.1038\/ncb2789","journal-title":"Nature Cell Biol"},{"key":"14_CR56","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","volume":"6","author":"Q Duan","year":"2020","unstructured":"Duan Q, Zhang H, Zheng J, Zhang L (2020) Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 6:605\u2013618. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.022","journal-title":"Trends Cancer"},{"key":"14_CR57","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/J.MAYOCP.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR (2019) Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 94:1623\u20131640. https:\/\/doi.org\/10.1016\/J.MAYOCP.2019.01.013","journal-title":"Mayo Clin Proc"},{"key":"14_CR58","doi-asserted-by":"publisher","unstructured":"Eales KL, Hollinshead KER, Tennant DA (2016) Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 5. https:\/\/doi.org\/10.1038\/oncsis.2015.50","DOI":"10.1038\/oncsis.2015.50"},{"key":"14_CR59","doi-asserted-by":"publisher","first-page":"e105038","DOI":"10.1371\/JOURNAL.PONE.0105038","volume":"9","author":"M Eilertsen","year":"2014","unstructured":"Eilertsen M, Andersen S, Al-Saad S et al (2014) Monocarboxylate transporters 1\u20134 in NSCLC: MCT1 Is an independent prognostic marker for survival. PLoS ONE 9:e105038. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0105038","journal-title":"PLoS ONE"},{"key":"14_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11030413","volume":"11","author":"K Eltayeb","year":"2022","unstructured":"Eltayeb K, La Monica S, Tiseo M et al (2022) Reprogramming of lipid metabolism in lung cancer: an overview with focus on EGFR-mutated non-small cell lung cancer. Cells 11:1\u201319. https:\/\/doi.org\/10.3390\/cells11030413","journal-title":"Cells"},{"key":"14_CR61","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (1979) 316:1039\u20131043. https:\/\/doi.org\/10.1126\/science.1141478","journal-title":"Science (1979)"},{"key":"14_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-8-41","volume":"8","author":"TWM Fan","year":"2009","unstructured":"Fan TWM, Lane AN, Higashi RM et al (2009) Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer 8:1\u201319. https:\/\/doi.org\/10.1186\/1476-4598-8-41","journal-title":"Mol Cancer"},{"key":"14_CR63","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1097\/JS9.0000000000001051","volume":"110","author":"A Fareed","year":"2024","unstructured":"Fareed A, Amir N, Ajaz H et al (2024) Advances in BRAF-targeted therapies for non-small cell lung cancer: the promise of encorafenib and binimetinib. Int J Surg 110:1891. https:\/\/doi.org\/10.1097\/JS9.0000000000001051","journal-title":"Int J Surg"},{"key":"14_CR64","doi-asserted-by":"publisher","unstructured":"Farhadi P, Yarani R, Dokaneheifard S, Mansouri K (2020) The emerging role of targeting cancer metabolism for cancer therapy. Tumor Biol 42. https:\/\/doi.org\/10.1177\/1010428320965284","DOI":"10.1177\/1010428320965284"},{"key":"14_CR65","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","volume":"171","author":"B Faubert","year":"2017","unstructured":"Faubert B, Li KY, Cai L et al (2017) Lactate metabolism in human lung tumors. Cell 171:358\u2013371. https:\/\/doi.org\/10.1016\/j.cell.2017.09.019","journal-title":"Cell"},{"key":"14_CR66","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.apsb.2022.10.023","volume":"13","author":"J Feng","year":"2023","unstructured":"Feng J, Lian Z, Xia X et al (2023) Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer. Acta Pharm Sin B 13:1145\u20131163. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.023","journal-title":"Acta Pharm Sin B"},{"key":"14_CR67","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1515\/oncologie-2024-0232","volume":"26","author":"X Feng","year":"2024","unstructured":"Feng X, Zhu B, Peng Y et al (2024) Functions of CAFs in microenvironment of non-small cell lung cancer: based on updated hallmarks of cancer. Oncologie 26:701\u2013709. https:\/\/doi.org\/10.1515\/oncologie-2024-0232","journal-title":"Oncologie"},{"key":"14_CR68","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41418-018-0101-z","volume":"25","author":"HR Fernandez","year":"2018","unstructured":"Fernandez HR, Gadre SM, Tan M et al (2018) The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ 25:1239\u20131258. https:\/\/doi.org\/10.1038\/s41418-018-0101-z","journal-title":"Cell Death Differ"},{"key":"14_CR69","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0046-8177(85)80083-6","volume":"16","author":"PL Fitzgibbons","year":"1985","unstructured":"Fitzgibbons PL, Kern WH (1985) Adenosquamous carcinoma of the lung: a clinical and pathologic study of seven cases. Hum Pathol 16:463\u2013466. https:\/\/doi.org\/10.1016\/S0046-8177(85)80083-6","journal-title":"Hum Pathol"},{"key":"14_CR70","first-page":"373","volume":"21","author":"T Fujii","year":"2016","unstructured":"Fujii T, Khawaja MR, DiNardo CD et al (2016) Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med 21:373\u2013380","journal-title":"Discov Med"},{"key":"14_CR71","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237\u20132246. https:\/\/doi.org\/10.1200\/JCO.2003.10.038","journal-title":"J Clin Oncol"},{"key":"14_CR72","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-07-2489","volume":"68","author":"E Furuta","year":"2008","unstructured":"Furuta E, Pai SK, Zhan R et al (2008) Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 68:1003\u20131011. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2489","journal-title":"Cancer Res"},{"key":"14_CR73","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G et al (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38:1505\u20131517. https:\/\/doi.org\/10.1200\/JCO.19.03136","journal-title":"J Clin Oncol"},{"key":"14_CR74","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cmet.2013.02.002","volume":"17","author":"PA Gameiro","year":"2013","unstructured":"Gameiro PA, Yang J, Metelo AM et al (2013) In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 17:372\u2013385. https:\/\/doi.org\/10.1016\/j.cmet.2013.02.002","journal-title":"Cell Metab"},{"key":"14_CR75","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMOA1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus Chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMOA1801005","journal-title":"N Engl J Med"},{"key":"14_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11960","volume":"7","author":"X Gao","year":"2016","unstructured":"Gao X, Lin SH, Ren F et al (2016) Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia. Nat Commun 7:11960. https:\/\/doi.org\/10.1038\/ncomms11960","journal-title":"Nat Commun"},{"key":"14_CR77","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrc1478","volume":"4","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis. Nat Rev Cancer 4:891\u2013899. https:\/\/doi.org\/10.1038\/nrc1478","journal-title":"Nat Rev Cancer"},{"key":"14_CR78","doi-asserted-by":"publisher","first-page":"786089","DOI":"10.3389\/FONC.2021.786089","volume":"11","author":"EAJ van Genugten","year":"2022","unstructured":"van Genugten EAJ, Weijers JAM, Heskamp S et al (2022) Imaging the rewired metabolism in lung cancer in relation to immune therapy. Front Oncol 11:786089. https:\/\/doi.org\/10.3389\/FONC.2021.786089","journal-title":"Front Oncol"},{"key":"14_CR79","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3390\/CANCERS11081141","volume":"11","author":"A Gkountakos","year":"2019","unstructured":"Gkountakos A, Sartori G, Falcone I et al (2019) PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around. Cancers (Basel) 11:1141. https:\/\/doi.org\/10.3390\/CANCERS11081141","journal-title":"Cancers (Basel)"},{"key":"14_CR80","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11:39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009","journal-title":"J Thorac Oncol"},{"key":"14_CR81","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12964-020-00568-z","volume":"18","author":"M Gong","year":"2020","unstructured":"Gong M, Li Y, Ye X et al (2020) Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1\/NRF2 pathway activation. Cell Commun Signal 18:98. https:\/\/doi.org\/10.1186\/s12964-020-00568-z","journal-title":"Cell Commun Signal"},{"key":"14_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12967-018-1543-2","volume":"16","author":"T Gong","year":"2018","unstructured":"Gong T, Cui L, Wang H et al (2018) Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1\u03b1-dependent glycolysis through inactivation of the PI3K\/Akt\/mTOR pathway. J Transl Med 16:1\u201310. https:\/\/doi.org\/10.1186\/S12967-018-1543-2","journal-title":"J Transl Med"},{"key":"14_CR83","doi-asserted-by":"publisher","unstructured":"Gouda MA, Voss MH, Tawbi H et al (2025) A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open 10:1\u201311. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104536","DOI":"10.1016\/j.esmoop.2025.104536"},{"key":"14_CR84","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","volume":"15","author":"PW Gout","year":"2001","unstructured":"Gout PW, Buckley AR, Simms CR, Bruchovsky N (2001) Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x-c cystine transporter: a new action for an old drug. Leukemia 15:1633\u20131640. https:\/\/doi.org\/10.1038\/sj.leu.2402238","journal-title":"Leukemia"},{"key":"14_CR85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2019.12.001","volume":"37","author":"J Goveia","year":"2020","unstructured":"Goveia J, Rohlenova K, Taverna F et al (2020) An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell 37:21\u201336. https:\/\/doi.org\/10.1016\/j.ccell.2019.12.001","journal-title":"Cancer Cell"},{"key":"14_CR86","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/J.CELL.2012.08.024","volume":"150","author":"R Govindan","year":"2012","unstructured":"Govindan R, Ding L, Griffith M et al (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121\u20131134. https:\/\/doi.org\/10.1016\/J.CELL.2012.08.024","journal-title":"Cell"},{"key":"14_CR87","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/J.SEMRADONC.2010.01.003","volume":"20","author":"EE Graves","year":"2010","unstructured":"Graves EE, Maity A, Le QT (2010) The tumor microenvironment in non\u2013small-cell lung cancer. Semin Radiat Oncol 20:156\u2013163. https:\/\/doi.org\/10.1016\/J.SEMRADONC.2010.01.003","journal-title":"Semin Radiat Oncol"},{"key":"14_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP et al (2015) Non-small-cell lung cancer. Nat Rev Dis Primers 1:1\u201316. https:\/\/doi.org\/10.1038\/nrdp.2015.9","journal-title":"Nat Rev Dis Primers"},{"key":"14_CR89","doi-asserted-by":"publisher","first-page":"1563303","DOI":"10.3389\/FIMMU.2025.1563303","volume":"16","author":"XY Gu","year":"2025","unstructured":"Gu XY, Yang JL, Lai R et al (2025) Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol 16:1563303. https:\/\/doi.org\/10.3389\/FIMMU.2025.1563303","journal-title":"Front Immunol"},{"key":"14_CR90","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/CANCERS12020404","volume":"12","author":"W Guo","year":"2020","unstructured":"Guo W, Tan HY, Chen F et al (2020) Targeting cancer metabolism to resensitize chemotherapy: potential development of cancer chemosensitizers from traditional chinese medicines. Cancers (Basel) 12:404. https:\/\/doi.org\/10.3390\/CANCERS12020404","journal-title":"Cancers (Basel)"},{"key":"14_CR91","doi-asserted-by":"publisher","first-page":"100583","DOI":"10.1016\/j.xinn.2024.100583","volume":"5","author":"J Gustafsson","year":"2024","unstructured":"Gustafsson J, Roshanzamir F, Hagnest\u00e5l A et al (2024) Metabolic collaboration between cells in the tumor microenvironment has a negligible effect on tumor growth. Innovation 5:100583. https:\/\/doi.org\/10.1016\/j.xinn.2024.100583","journal-title":"Innovation"},{"key":"14_CR92","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1136\/bmj.315.7114.980","volume":"315","author":"AK Hackshaw","year":"1997","unstructured":"Hackshaw AK, Law MR, Wald NJ (1997) The accumulated evidence on lung cancer and environmental tobacco smoke. Br Med J 315:980\u2013988. https:\/\/doi.org\/10.1136\/bmj.315.7114.980","journal-title":"Br Med J"},{"key":"14_CR93","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"PS Hammerman","year":"2012","unstructured":"Hammerman PS, Voet D, Lawrence MS et al (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519\u2013525. https:\/\/doi.org\/10.1038\/nature11404","journal-title":"Nature"},{"key":"14_CR94","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309\u2013322. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.022","journal-title":"Cancer Cell"},{"key":"14_CR95","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/J.NEO.2019.03.009","volume":"21","author":"J Hao","year":"2019","unstructured":"Hao J, Zeltz C, Pintilie M et al (2019) Characterization of distinct populations of carcinoma-associated fibroblasts from non\u2013small cell lung carcinoma reveals a role for ST8SIA2 in cancer cell invasion. Neoplasia 21:482\u2013493. https:\/\/doi.org\/10.1016\/J.NEO.2019.03.009","journal-title":"Neoplasia"},{"key":"14_CR96","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3390\/BIOM14121646","volume":"14","author":"ZN Hao","year":"2024","unstructured":"Hao ZN, Tan XP, Zhang Q et al (2024) Lactate and lactylation: dual regulators of T-cell-mediated tumor immunity and immunotherapy. Biomolecules 14:1646. https:\/\/doi.org\/10.3390\/BIOM14121646","journal-title":"Biomolecules"},{"key":"14_CR97","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/J.TCB.2020.03.002","volume":"30","author":"IS Harris","year":"2020","unstructured":"Harris IS, DeNicola GM (2020) The complex interplay between antioxidants and ROS in cancer. Trends Cell Biol 30:440\u2013451. https:\/\/doi.org\/10.1016\/J.TCB.2020.03.002","journal-title":"Trends Cell Biol"},{"key":"14_CR98","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-12-2334","volume":"19","author":"M Hassanein","year":"2013","unstructured":"Hassanein M, Hoeksema MD, Shiota M et al. (2013) SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 19:560\u2013570. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2334","journal-title":"Clin Cancer Res"},{"key":"14_CR99","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/IJC.29535","volume":"137","author":"M Hassanein","year":"2015","unstructured":"Hassanein M, Qian J, Hoeksema MD et al (2015) Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. Int J Cancer 137:1587\u20131597. https:\/\/doi.org\/10.1002\/IJC.29535","journal-title":"Int J Cancer"},{"key":"14_CR100","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133\u2013150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nat Rev Cancer"},{"key":"14_CR101","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (1979) 324:1029\u20131033. https:\/\/doi.org\/10.1126\/science.1160809","journal-title":"Science (1979)"},{"key":"14_CR102","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu T-E, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1801946","journal-title":"N Engl J Med"},{"key":"14_CR103","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer. N Engl J Med 381:2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"14_CR104","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/J.JTHO.2020.11.015","volume":"16","author":"JA Hellyer","year":"2021","unstructured":"Hellyer JA, Padda SK, Diehn M, Wakelee HA (2021) Clinical implications of KEAP1-NFE2L2 mutations in NSCLC. J Thorac Oncol 16:395\u2013403. https:\/\/doi.org\/10.1016\/J.JTHO.2020.11.015","journal-title":"J Thorac Oncol"},{"key":"14_CR105","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","volume":"164","author":"CT Hensley","year":"2016","unstructured":"Hensley CT, Faubert B, Yuan Q et al (2016) Metabolic heterogeneity in human lung tumors. Cell 164:681\u2013694. https:\/\/doi.org\/10.1016\/j.cell.2015.12.034","journal-title":"Cell"},{"key":"14_CR106","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMRA0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367\u20131380. https:\/\/doi.org\/10.1056\/NEJMRA0802714","journal-title":"N Engl J Med"},{"key":"14_CR107","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"14_CR108","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553:446\u2013454. https:\/\/doi.org\/10.1038\/nature25183","journal-title":"Nature"},{"key":"14_CR109","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.3390\/IJMS20236016","volume":"20","author":"M Herrera","year":"2019","unstructured":"Herrera M, Galindo-Pumari\u00f1o C, Garc\u00eda-Barber\u00e1n V, Pe\u00f1a C (2019) A snapshot of the tumor microenvironment in colorectal cancer: the liquid biopsy. Int J Mol Sci 20:6016. https:\/\/doi.org\/10.3390\/IJMS20236016","journal-title":"Int J Mol Sci"},{"key":"14_CR110","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-3-030-34025-4_16","volume":"1219","author":"A Hip\u00f3lito","year":"2020","unstructured":"Hip\u00f3lito A, Mendes C, Serpa J (2020) The metabolic remodelling in lung cancer and its putative consequence in therapy response. Adv Exp Med Biol 1219:311\u2013333. https:\/\/doi.org\/10.1007\/978-3-030-34025-4_16","journal-title":"Adv Exp Med Biol"},{"key":"14_CR111","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/ANTIOX13010051\/S1","volume":"13","author":"A Hip\u00f3lito","year":"2024","unstructured":"Hip\u00f3lito A, Mendes C, Martins F et al (2024) H2S-synthesizing enzymes are putative determinants in lung cancer management toward personalized medicine. Antioxidants 13:51. https:\/\/doi.org\/10.3390\/ANTIOX13010051\/S1","journal-title":"Antioxidants"},{"key":"14_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"6736","author":"FR Hirsch","year":"2016","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL et al (2016) Lung cancer: current therapies and new targeted treatments. The Lancet 6736:1\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(16)30958-8","journal-title":"The Lancet"},{"key":"14_CR113","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/FONC.2018.00170","volume":"8","author":"J Hlouschek","year":"2018","unstructured":"Hlouschek J, Hansel C, Jendrossek V, Matschke J (2018) The mitochondrial citrate carrier (SLC25A1) sustains redox homeostasis and mitochondrial metabolism supporting radioresistance of cancer cells with tolerance to cycling severe hypoxia. Front Oncol 8:170. https:\/\/doi.org\/10.3389\/FONC.2018.00170","journal-title":"Front Oncol"},{"key":"14_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers9080107","volume":"9","author":"P Hofman","year":"2017","unstructured":"Hofman P (2017) ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers (Basel) 9:1\u201316. https:\/\/doi.org\/10.3390\/cancers9080107","journal-title":"Cancers (Basel)"},{"key":"14_CR115","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF01076071","volume":"152","author":"AL Holleran","year":"1995","unstructured":"Holleran AL, Briscoe DA, Fiskum G, Kelleher JK (1995) Glutamine metabolism in AS-30D hepatoma cells. Evidence for its conversion into lipids via reductive carboxylation. Mol Cell Biochem 152:95\u2013101. https:\/\/doi.org\/10.1007\/BF01076071","journal-title":"Mol Cell Biochem"},{"key":"14_CR116","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cellsig.2016.01.011","volume":"28","author":"SY Hong","year":"2016","unstructured":"Hong SY, Yu FX, Luo Y, Hagen T (2016) Oncogenic activation of the PI3K\/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. Cell Signal 28:377\u2013383. https:\/\/doi.org\/10.1016\/j.cellsig.2016.01.011","journal-title":"Cell Signal"},{"key":"14_CR117","doi-asserted-by":"publisher","first-page":"325058","DOI":"10.3389\/FPHAR.2018.00043","volume":"9","author":"W Hong","year":"2018","unstructured":"Hong W, Cai P, Xu C et al (2018) Inhibition of glucose-6-phosphate dehydrogenase reverses cisplatin resistance in lung cancer cells via the redox system. Front Pharmacol 9:325058. https:\/\/doi.org\/10.3389\/FPHAR.2018.00043","journal-title":"Front Pharmacol"},{"key":"14_CR118","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","volume":"39","author":"H Hu","year":"2021","unstructured":"Hu H, Piotrowska Z, Hare PJ et al (2021) Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell 39:1531\u20131547. https:\/\/doi.org\/10.1016\/j.ccell.2021.09.003","journal-title":"Cancer Cell"},{"key":"14_CR119","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.celrep.2014.08.028","volume":"8","author":"D Huang","year":"2014","unstructured":"Huang D, Li T, Li X et al (2014) HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep 8:1930\u20131942. https:\/\/doi.org\/10.1016\/j.celrep.2014.08.028","journal-title":"Cell Rep"},{"key":"14_CR120","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-019-1120-4","volume":"38","author":"Q Huang","year":"2019","unstructured":"Huang Q, Wang Q, Li D et al (2019) Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res 38:129. https:\/\/doi.org\/10.1186\/s13046-019-1120-4","journal-title":"J Exp Clin Cancer Res"},{"key":"14_CR121","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.21037\/TLCR-20-153","volume":"9","author":"YP Hung","year":"2020","unstructured":"Hung YP, Chirieac LR (2020) How should molecular findings be integrated in the classification for lung cancer. Transl Lung Cancer Res 9:2245\u20132254. https:\/\/doi.org\/10.21037\/TLCR-20-153","journal-title":"Transl Lung Cancer Res"},{"key":"14_CR122","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1158\/1055-9965.EPI-18-0629","volume":"28","author":"J Huo","year":"2019","unstructured":"Huo J, Hong YR, Bian J et al. (2019) Low rates of patient-reported physician-patient discussion about lung cancer screening among current smokers: data from Health Information National Trends survey. Cancer Epidemiol Biomarkers Prev 28:963\u2013973. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0629","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"14_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FONC.2017.00193","volume":"7","author":"K Inamura","year":"2017","unstructured":"Inamura K (2017) Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol 7:1\u20137. https:\/\/doi.org\/10.3389\/FONC.2017.00193","journal-title":"Front Oncol"},{"key":"14_CR124","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.3390\/IJMS22115703","volume":"22","author":"V Infantino","year":"2021","unstructured":"Infantino V, Santarsiero A, Convertini P et al (2021) Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci 2021 22:5703. https:\/\/doi.org\/10.3390\/IJMS22115703","journal-title":"Int J Mol Sci 2021"},{"key":"14_CR125","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semcdb.2015.08.004","volume":"43","author":"WJ Israelsen","year":"2015","unstructured":"Israelsen WJ, Vander Heiden MG (2015) Pyruvate kinase: function, regulation and role in cancer. Semin Cell Dev Biol 43:43\u201351. https:\/\/doi.org\/10.1016\/j.semcdb.2015.08.004","journal-title":"Semin Cell Dev Biol"},{"key":"14_CR126","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/JCP.25859","volume":"233","author":"R Jahanban-Esfahlan","year":"2018","unstructured":"Jahanban-Esfahlan R, de la Guardia M, Ahmadi D, Yousefi B (2018) Modulating tumor hypoxia by nanomedicine for effective cancer therapy. J Cell Physiol 233:2019\u20132031. https:\/\/doi.org\/10.1002\/JCP.25859","journal-title":"J Cell Physiol"},{"key":"14_CR127","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1200\/JCO.23.02744","volume":"42","author":"IA Jaiyesimi","year":"2024","unstructured":"Jaiyesimi IA, Leighl NB, Ismaila N et al (2024) Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol 42:E1\u2013E22. https:\/\/doi.org\/10.1200\/JCO.23.02744","journal-title":"J Clin Oncol"},{"key":"14_CR128","doi-asserted-by":"publisher","first-page":"176912","DOI":"10.1016\/J.EJPHAR.2024.176912","volume":"982","author":"A Jamshidi-Parsian","year":"2024","unstructured":"Jamshidi-Parsian A, Jenkins SV, Tran A et al (2024) CB-839 induces reversible dormancy in lung tumor-cells. Eur J Pharmacol 982:176912. https:\/\/doi.org\/10.1016\/J.EJPHAR.2024.176912","journal-title":"Eur J Pharmacol"},{"key":"14_CR129","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMOA1411817","volume":"372","author":"PA J\u00e4nne","year":"2015","unstructured":"J\u00e4nne PA, Yang JC-H, Kim D-W et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689\u20131699. https:\/\/doi.org\/10.1056\/NEJMOA1411817","journal-title":"N Engl J Med"},{"key":"14_CR130","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/S00408-025-00801-X","volume":"203","author":"H Jeon","year":"2025","unstructured":"Jeon H, Wang S, Song J et al (2025) Update 2025: management of non-small-cell. Lung Cancer. Lung 203:53. https:\/\/doi.org\/10.1007\/S00408-025-00801-X","journal-title":"Lung Cancer. Lung"},{"issue":"36","key":"14_CR131","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/S41388-018-0307-Z","volume":"37","author":"X Ji","year":"2018","unstructured":"Ji X, Qian J, Rahman SMJ, et al (2018) xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene 37(36):5007\u20135019.\u2009https:\/\/doi.org\/10.1038\/s41388-018-0307-z","journal-title":"Oncogene"},{"issue":"36","key":"14_CR132","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/s41388-018-0307-z","volume":"37","author":"X Ji","year":"2018","unstructured":"Ji X, Qian J, Rahman SMJ et al (2018) xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene 37(36):5007\u20135019.\u2009https:\/\/doi.org\/10.1038\/s41388-018-0307-z","journal-title":"Oncogene"},{"key":"14_CR133","doi-asserted-by":"publisher","first-page":"102754","DOI":"10.1016\/J.REDOX.2023.102754","volume":"63","author":"H Jiang","year":"2023","unstructured":"Jiang H, Zuo J, Li B et al (2023) Drug-induced oxidative stress in cancer treatments: angel or devil. Redox Biol 63:102754. https:\/\/doi.org\/10.1016\/J.REDOX.2023.102754","journal-title":"Redox Biol"},{"key":"14_CR134","doi-asserted-by":"publisher","first-page":"1492050","DOI":"10.3389\/fimmu.2024.1492050","volume":"15","author":"M Jiang","year":"2024","unstructured":"Jiang M, Wang Y, Zhao X, Yu J (2024) From metabolic byproduct to immune modulator: the role of lactate in tumor immune escape. Front Immunol 15:1492050. https:\/\/doi.org\/10.3389\/fimmu.2024.1492050","journal-title":"Front Immunol"},{"key":"14_CR135","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/S13238-014-0082-8","volume":"5","author":"P Jiang","year":"2014","unstructured":"Jiang P, Du W, Wu M (2014) Regulation of the pentose phosphate pathway in cancer. Protein Cell 5:592\u2013602. https:\/\/doi.org\/10.1007\/S13238-014-0082-8","journal-title":"Protein Cell"},{"key":"14_CR136","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.lungcan.2009.11.012","volume":"69","author":"G Jin","year":"2010","unstructured":"Jin G, Kim MJ, Jeon HS et al (2010) PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69:279\u2013283. https:\/\/doi.org\/10.1016\/j.lungcan.2009.11.012","journal-title":"Lung Cancer"},{"key":"14_CR137","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I et al (2020) Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol 15:1351\u20131360. https:\/\/doi.org\/10.1016\/j.jtho.2020.03.028","journal-title":"J Thorac Oncol"},{"key":"14_CR138","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"GP Kalemkerian","year":"2018","unstructured":"Kalemkerian GP, Narula N, Kennedy EB et al (2018) Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists\/International Association for the. J Clin Oncol 36:911\u2013919. https:\/\/doi.org\/10.1200\/JCO.2017.76.7293","journal-title":"J Clin Oncol"},{"key":"14_CR139","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/J.REDOX.2017.04.018","volume":"12","author":"B Kalyanaraman","year":"2017","unstructured":"Kalyanaraman B (2017) Teaching the basics of cancer metabolism: developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism. Redox Biol 12:833\u2013842. https:\/\/doi.org\/10.1016\/J.REDOX.2017.04.018","journal-title":"Redox Biol"},{"key":"14_CR140","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature12154","volume":"498","author":"J Kaplon","year":"2013","unstructured":"Kaplon J, Zheng L, Meissl K et al (2013) A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498:109\u2013112. https:\/\/doi.org\/10.1038\/nature12154","journal-title":"Nature"},{"key":"14_CR141","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1073\/pnas.1603735113","volume":"113","author":"K Kapoor","year":"2016","unstructured":"Kapoor K, Finer-Moore JS, Pedersen BP et al (2016) Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides. Proc Natl Acad Sci USA 113:4711\u20134716. https:\/\/doi.org\/10.1073\/pnas.1603735113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR142","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3978\/j.issn.2218-6751.2016.01.02","volume":"5","author":"N Karachaliou","year":"2016","unstructured":"Karachaliou N, Pilotto S, Lazzari C et al (2016) Cellular and molecular biology of small cell lung cancer: an overview. Transl Lung Cancer Res 5:2. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2016.01.02","journal-title":"Transl Lung Cancer Res"},{"key":"14_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS11050599","volume":"11","author":"J Kashima","year":"2019","unstructured":"Kashima J, Kitadai R, Okuma Y (2019) Molecular and morphological profiling of lung cancer: a foundation for \u201cNext-Generation\u201d pathologists and oncologists. Cancers (Basel) 11:1\u201319. https:\/\/doi.org\/10.3390\/CANCERS11050599","journal-title":"Cancers (Basel)"},{"key":"14_CR144","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1158\/1078-0432.CCR-14-2791","volume":"21","author":"R Katayama","year":"2015","unstructured":"Katayama R, Lovly CM, Shaw AT (2015) Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 21:2227\u20132235. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2791","journal-title":"Clin Cancer Res"},{"key":"14_CR145","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1634\/THEONCOLOGIST.2015-0507","volume":"21","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Suzman DL, Blumenthal G et al (2016) FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 21:634\u2013642. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2015-0507","journal-title":"Oncologist"},{"key":"14_CR146","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/febs.14125","volume":"285","author":"EM Kerr","year":"2018","unstructured":"Kerr EM, Martins CP (2018) Metabolic rewiring in mutant Kras lung cancer. FEBS J 285:28\u201341. https:\/\/doi.org\/10.1111\/febs.14125","journal-title":"FEBS J"},{"key":"14_CR147","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.3390\/CANCERS13133164","volume":"13","author":"K Khaddour","year":"2021","unstructured":"Khaddour K, Jonna S, Deneka A et al (2021) Targeting the epidermal growth factor receptor in EGFR-mutated lung cancer: current and emerging therapies. Cancers (Basel) 13:3164. https:\/\/doi.org\/10.3390\/CANCERS13133164","journal-title":"Cancers (Basel)"},{"key":"14_CR148","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3892\/OL.2012.1054","volume":"5","author":"K Kim","year":"2013","unstructured":"Kim K, An S, Cha HJ et al (2013) Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncol Lett 5:588\u2013592. https:\/\/doi.org\/10.3892\/OL.2012.1054","journal-title":"Oncol Lett"},{"key":"14_CR149","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4062\/BIOMOLTHER.2015.013","volume":"23","author":"SY Kim","year":"2015","unstructured":"Kim SY (2015) Cancermetabolism: strategic diversion from targeting cancer drivers to targeting cancer suppliers. Biomol Ther (Seoul) 23:109. https:\/\/doi.org\/10.4062\/BIOMOLTHER.2015.013","journal-title":"Biomol Ther (Seoul)"},{"key":"14_CR150","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMOA044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786\u2013792. https:\/\/doi.org\/10.1056\/NEJMOA044238","journal-title":"N Engl J Med"},{"key":"14_CR151","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.18632\/ONCOTARGET.1831","volume":"5","author":"VK Kolukula","year":"2014","unstructured":"Kolukula VK, Sahu G, Wellstein A et al (2014) SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Oncotarget 5:1212\u20131225. https:\/\/doi.org\/10.18632\/ONCOTARGET.1831","journal-title":"Oncotarget"},{"key":"14_CR152","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ de Koning","year":"2020","unstructured":"de Koning HJ, van der Aalst CM, de Jong PA et al (2020) Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 382:503\u2013513. https:\/\/doi.org\/10.1056\/NEJMoa1911793","journal-title":"N Engl J Med"},{"key":"14_CR153","doi-asserted-by":"publisher","first-page":"102649","DOI":"10.1016\/j.isci.2021.102649","volume":"24","author":"P Koppula","year":"2021","unstructured":"Koppula P, Olszewski K, Zhang Y et al (2021) KEAP1 deficiency drives glucose dependency and sensitizes lung cancer cells and tumors to GLUT inhibition. iScience 24:102649. https:\/\/doi.org\/10.1016\/j.isci.2021.102649","journal-title":"iScience"},{"key":"14_CR154","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fimmu.2018.00353","volume":"9","author":"S Kouidhi","year":"2018","unstructured":"Kouidhi S, Ayed FBen, Elgaaied AB (2018) Targeting tumor metabolism: a new challenge to improve immunotherapy. Front Immunol 9:353. https:\/\/doi.org\/10.3389\/fimmu.2018.00353","journal-title":"Front Immunol"},{"key":"14_CR155","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/JAMA.290.16.2149","volume":"290","author":"MG Kris","year":"2003","unstructured":"Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J. Am. Med. Assoc. 290:2149\u20132158. https:\/\/doi.org\/10.1001\/JAMA.290.16.2149","journal-title":"J. Am. Med. Assoc."},{"key":"14_CR156","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/JAMA.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. J. Am. Med. Assoc. 311:1998\u20132006. https:\/\/doi.org\/10.1001\/JAMA.2014.3741","journal-title":"J. Am. Med. Assoc."},{"key":"14_CR157","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.3390\/IJMS20184411","volume":"20","author":"A Kr\u00fcger-Genge","year":"2019","unstructured":"Kr\u00fcger-Genge A, Blocki A, Franke RP, Jung F (2019) Vascularendothelial cell biology: an update. Int J Mol Sci 20:4411. https:\/\/doi.org\/10.3390\/IJMS20184411","journal-title":"Int J Mol Sci"},{"key":"14_CR158","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<857::AID-IJC20>3.0.CO;2-U","volume":"85","author":"W Kuo","year":"2000","unstructured":"Kuo W, Lin J, Tang TK (2000) Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer 85:857\u2013864","journal-title":"Int J Cancer"},{"key":"14_CR159","doi-asserted-by":"publisher","unstructured":"Kurtoglu M, Maher JC, Lampidis TJ (2007) Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. https:\/\/home.liebertpub.com\/ars 9:1383\u20131390. https:\/\/doi.org\/10.1089\/ARS.2007.1714","DOI":"10.1089\/ARS.2007.1714"},{"key":"14_CR160","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1053\/J.GASTRO.2017.01.021","volume":"152","author":"KKY Lai","year":"2017","unstructured":"Lai KKY, Kweon SM, Chi F et al (2017) Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a Wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6. Gastroenterology 152:1477\u20131491. https:\/\/doi.org\/10.1053\/J.GASTRO.2017.01.021","journal-title":"Gastroenterology"},{"key":"14_CR161","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","volume":"24","author":"D Lambrechts","year":"2018","unstructured":"Lambrechts D, Wauters E, Boeckx B et al (2018) Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med 24:1277\u20131289. https:\/\/doi.org\/10.1038\/s41591-018-0096-5","journal-title":"Nat Med"},{"issue":"1","key":"14_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-50157-8","volume":"15","author":"T Lan","year":"2024","unstructured":"Lan T, Arastu S, Lam J et al (2024) Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer. Nat Commun 15(1):1\u201318. https:\/\/doi.org\/10.1038\/s41467-024-50157-8 2024 15:1","journal-title":"Nat Commun"},{"key":"14_CR163","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3390\/CANCERS16162779","volume":"16","author":"P Lavaud","year":"2024","unstructured":"Lavaud P, Bortolot M, Zullo L et al (2024) Early-stage non-small cell lung cancer: new challenges with immune checkpoint blockers and targeted therapies. Cancers (Basel) 16:2779. https:\/\/doi.org\/10.3390\/CANCERS16162779","journal-title":"Cancers (Basel)"},{"key":"14_CR164","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/CELLS10092371","volume":"10","author":"SH Lee","year":"2021","unstructured":"Lee SH, Golinska M, Griffiths JR (2021) HIF-1-independent mechanisms regulating metabolic adaptation in hypoxic cancer cells. Cells 10:2371. https:\/\/doi.org\/10.3390\/CELLS10092371","journal-title":"Cells"},{"key":"14_CR165","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbcan.2015.08.002","volume":"1856","author":"H Lemjabbar-Alaoui","year":"2015","unstructured":"Lemjabbar-Alaoui H, Hassan OUI, Yang Y-W, Buchanan P (2015) Lung cancer: biology and treatment options. Biochim Biophys Acta 1856:189\u2013210. https:\/\/doi.org\/10.1016\/j.bbcan.2015.08.002","journal-title":"Biochim Biophys Acta"},{"key":"14_CR166","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366:","author":"RD Leone","year":"2019","unstructured":"Leone RD, Zhao L, Englert JM et al (2019) Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science (1979) 366:1013\u20131021. https:\/\/doi.org\/10.1126\/science.aav2588","journal-title":"Science (1979)"},{"key":"14_CR167","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1002\/cncr.28749","volume":"120","author":"DR Lewis","year":"2014","unstructured":"Lewis DR, Check DP, Caporaso NE et al (2014) US lung cancer trends by histologic type. Cancer 120:2883\u20132892. https:\/\/doi.org\/10.1002\/cncr.28749","journal-title":"Cancer"},{"key":"14_CR168","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/BIOMEDICINES11020475\/S1","volume":"11","author":"H Li","year":"2023","unstructured":"Li H, Li JJ, Lu W et al (2023) Targeting mitochondrial IDH2 enhances antitumor activity of cisplatin in lung cancer via ROS-mediated mechanism. Biomedicines 11:475. https:\/\/doi.org\/10.3390\/BIOMEDICINES11020475\/S1","journal-title":"Biomedicines"},{"key":"14_CR169","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.3892\/or.2016.4714","volume":"35","author":"J Li","year":"2016","unstructured":"Li J, Guan J, Long X et al (2016) mir-1-mediated paracrine effect of cancer-associated fibroblasts on lung cancer cell proliferation and chemoresistance. Oncol Rep 35:3523\u20133531","journal-title":"Oncol Rep"},{"key":"14_CR170","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.3390\/MOLECULES25204831","volume":"25","author":"J Li","year":"2020","unstructured":"Li J, Eu JQ, Kong LR et al (2020) Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy. Molecules 25:4831. https:\/\/doi.org\/10.3390\/MOLECULES25204831","journal-title":"Molecules"},{"key":"14_CR171","doi-asserted-by":"publisher","first-page":"32586","DOI":"10.18632\/ONCOTARGET.15937","volume":"8","author":"W Li","year":"2017","unstructured":"Li W, Gao F, Ma X et al (2017) Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis. Oncotarget 8:32586. https:\/\/doi.org\/10.18632\/ONCOTARGET.15937","journal-title":"Oncotarget"},{"key":"14_CR172","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/S11010-017-3258-8","volume":"445","author":"X Li","year":"2018","unstructured":"Li X, Liu J, Qian L et al (2018) Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy. Mol Cell Biochem 445:123\u2013134. https:\/\/doi.org\/10.1007\/S11010-017-3258-8","journal-title":"Mol Cell Biochem"},{"key":"14_CR173","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/CANCERS14112735","volume":"14","author":"J Lidonnici","year":"2022","unstructured":"Lidonnici J, Santoro MM, Oberkersch RE (2022) Cancer-induced metabolic rewiring of tumor endothelial cells. Cancers (Basel) 14:2735. https:\/\/doi.org\/10.3390\/CANCERS14112735","journal-title":"Cancers (Basel)"},{"key":"14_CR174","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/J.CELL.2019.06.003","volume":"178","author":"L Lignitto","year":"2019","unstructured":"Lignitto L, LeBoeuf SE, Homer H et al (2019) Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell 178:316. https:\/\/doi.org\/10.1016\/J.CELL.2019.06.003","journal-title":"Cell"},{"key":"14_CR175","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/S13046-019-1214-Z","volume":"38","author":"J Lin","year":"2019","unstructured":"Lin J, Xia L, Liang J et al (2019) The roles of glucose metabolic reprogramming in chemo- and radio-resistance. J Exp Clin Cancer Res 38:218. https:\/\/doi.org\/10.1186\/S13046-019-1214-Z","journal-title":"J Exp Clin Cancer Res"},{"key":"14_CR176","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5858\/ARPA.2017-0388-CP","volume":"142","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 142:321\u2013346. https:\/\/doi.org\/10.5858\/ARPA.2017-0388-CP","journal-title":"Arch Pathol Lab Med"},{"key":"14_CR177","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.semcdb.2019.05.016","volume":"98","author":"C Vander Linden","year":"2019","unstructured":"Vander Linden C, Corbet C (2019) Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology. Semin Cell Dev Biol 98:202\u2013210. https:\/\/doi.org\/10.1016\/j.semcdb.2019.05.016","journal-title":"Semin Cell Dev Biol"},{"key":"14_CR178","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.ymthe.2020.08.021","volume":"28","author":"J Liu","year":"2020","unstructured":"Liu J, Xia X, Huang P (2020) xCT: a critical molecule that links cancer metabolism to redox signaling. Mol Ther 28:2358\u20132366. https:\/\/doi.org\/10.1016\/j.ymthe.2020.08.021","journal-title":"Mol Ther"},{"issue":"8","key":"14_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-06078-3","volume":"14","author":"LZ Liu","year":"2023","unstructured":"Liu LZ, Wang B, Zhang R et al (2023) The activated CD36-Src axis promotes lung adenocarcinoma cell proliferation and actin remodeling-involved metastasis in high-fat environment. Cell Death Dis 14(8):1\u201315. https:\/\/doi.org\/10.1038\/s41419-023-06078-3","journal-title":"Cell Death Dis"},{"key":"14_CR180","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3892\/or.2016.5253","volume":"37","author":"T Liu","year":"2016","unstructured":"Liu T, Yin H (2016) PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer. Oncol Rep 37:193\u2013200","journal-title":"Oncol Rep"},{"key":"14_CR181","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3892\/or.2016.5253","volume":"37","author":"T Liu","year":"2017","unstructured":"Liu T, Yin H (2017) PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer. Oncol Rep 37:193\u2013200. https:\/\/doi.org\/10.3892\/or.2016.5253","journal-title":"Oncol Rep"},{"key":"14_CR182","doi-asserted-by":"publisher","first-page":"448751","DOI":"10.3389\/FCELL.2019.00060","volume":"7","author":"T Liu","year":"2019","unstructured":"Liu T, Zhou L, Li D et al (2019) Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol 7:448751. https:\/\/doi.org\/10.3389\/FCELL.2019.00060","journal-title":"Front Cell Dev Biol"},{"key":"14_CR183","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/S13277-014-2639-9","volume":"36","author":"X Liu","year":"2015","unstructured":"Liu X, Pei C, Yan S et al (2015) NADPH oxidase 1-dependent ROS is crucial for TLR4 signaling to promote tumor metastasis of non-small cell lung cancer. Tumor Biol 36:1493\u20131502. https:\/\/doi.org\/10.1007\/S13277-014-2639-9","journal-title":"Tumor Biol"},{"key":"14_CR184","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/1535-7163.MCT-13-0302","volume":"12","author":"Y Long","year":"2013","unstructured":"Long Y, Tsai W Bin, Wangpaichitr M et al (2013) Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther 12:2581\u20132590. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0302","journal-title":"Mol Cancer Ther"},{"key":"14_CR185","doi-asserted-by":"publisher","unstructured":"Lopes-Coelho F, Gouveia-Fernandes S, Serpa J (2018) Metabolic cooperation between cancer and non-cancerous stromal cells is pivotal in cancer progression. Tumor Biol 40:1\u201315. https:\/\/doi.org\/10.1177\/1010428318756203","DOI":"10.1177\/1010428318756203"},{"key":"14_CR186","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","volume":"24","author":"A Luengo","year":"2017","unstructured":"Luengo A, Gui DY, Vander Heiden MG (2017) Targeting metabolism for cancer therapy. Cell Chem Biol 24:1161\u20131180. https:\/\/doi.org\/10.1016\/j.chembiol.2017.08.028","journal-title":"Cell Chem Biol"},{"key":"14_CR187","doi-asserted-by":"publisher","first-page":"102006","DOI":"10.1016\/J.REDOX.2021.102006","volume":"43","author":"G Luis","year":"2021","unstructured":"Luis G, Godfroid A, Nishiumi S et al (2021) Tumor resistance to ferroptosis driven by stearoyl-CoA desaturase-1 (SCD1) in cancer cells and fatty acid biding protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol 43:102006. https:\/\/doi.org\/10.1016\/J.REDOX.2021.102006","journal-title":"Redox Biol"},{"key":"14_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40364-022-00412-1","volume":"10","author":"L Lv","year":"2022","unstructured":"Lv L, Huang R Han, Li J et al (2022) Impact of NSCLC metabolic remodeling on immunotherapy effectiveness. Biomark Res 10:1\u201313. https:\/\/doi.org\/10.1186\/S40364-022-00412-1","journal-title":"Biomark Res"},{"key":"14_CR189","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMOA040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMOA040938","journal-title":"N Engl J Med"},{"key":"14_CR190","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/S40170-024-00366-Y","volume":"12","author":"N Lypova","year":"2024","unstructured":"Lypova N, Dougherty SM, Clem BF et al (2024) PFKFB3-dependent redox homeostasis and DNA repair support cell survival under EGFR-TKIs in non-small cell lung carcinoma. Cancer Metab 12:37. https:\/\/doi.org\/10.1186\/S40170-024-00366-Y","journal-title":"Cancer Metab"},{"key":"14_CR191","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMOA0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388. https:\/\/doi.org\/10.1056\/NEJMOA0909530","journal-title":"N Engl J Med"},{"key":"14_CR192","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"S Maleki Vareki","year":"2018","unstructured":"Maleki Vareki S (2018) High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J\u00a0Immunother Cancer 6:157. https:\/\/doi.org\/10.1186\/s40425-018-0479-7","journal-title":"J Immunother Cancer"},{"key":"14_CR193","doi-asserted-by":"publisher","first-page":"79895","DOI":"10.7554\/ELIFE.79895","volume":"11","author":"S Mansouri","year":"2022","unstructured":"Mansouri S, Heylmann D, Stiewe T et al (2022) Cancer genome and tumor microenvironment: reciprocal crosstalk shapes lung cancer plasticity. eLife 11:79895. https:\/\/doi.org\/10.7554\/ELIFE.79895","journal-title":"eLife"},{"key":"14_CR194","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","volume":"29","author":"A Marchetti","year":"2011","unstructured":"Marchetti A, Felicioni L, Malatesta S et al (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J\u00a0Clin Oncol 29:3574\u20133579. https:\/\/doi.org\/10.1200\/JCO.2011.35.9638","journal-title":"J Clin Oncol"},{"issue":"1","key":"14_CR195","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","volume":"14","author":"UE Martinez-Outschoorn","year":"2017","unstructured":"Martinez-Outschoorn UE, Peiris-Pag\u00e9s M, Pestell RG et al (2017) Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 14(1):11\u201331. https:\/\/doi.org\/10.1038\/nrclinonc.2016.60","journal-title":"Nat Rev Clin Oncol"},{"key":"14_CR196","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez-Reyes","year":"2021","unstructured":"Mart\u00ednez-Reyes I, Chandel NS (2021) Cancer metabolism: looking forward. Nat Rev Cancer 21:669\u2013680. https:\/\/doi.org\/10.1038\/s41568-021-00378-6","journal-title":"Nat Rev Cancer"},{"key":"14_CR197","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41417-025-00906-8","volume":"32","author":"F Martins","year":"2025","unstructured":"Martins F, Arada R, Barros H et al (2025) Lactate-coated polyurea-siRNA dendriplex: a gene therapy-directed and metabolism-based strategy to impair glioblastoma (GBM. Cancer Gene Ther 32:690\u2013705. https:\/\/doi.org\/10.1038\/s41417-025-00906-8","journal-title":"Cancer Gene Ther"},{"key":"14_CR198","unstructured":"Martins FAD (2019) Metabolic remodeling of endothelial cells upon hypoxia and \u03b2-blockers as anti-angiogenic drugs. Faculdade de Ci\u00eancias, Universidade de Lisboa"},{"key":"14_CR199","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 30:1321\u20131328. https:\/\/doi.org\/10.1093\/annonc\/mdz167","journal-title":"Ann Oncol"},{"key":"14_CR200","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/J.LUNGCAN.2018.10.016","volume":"126","author":"TWH Meijer","year":"2018","unstructured":"Meijer TWH, Peeters WJM, Dubois LJ et al (2018) Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer. Lung Cancer 126:32\u201340. https:\/\/doi.org\/10.1016\/J.LUNGCAN.2018.10.016","journal-title":"Lung Cancer"},{"key":"14_CR201","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1111\/1759-7714.13226","volume":"10","author":"TWH Meijer","year":"2019","unstructured":"Meijer TWH, Looijen-Salamon MG, Lok J et al (2019) Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes. Thorac Cancer 10:2289. https:\/\/doi.org\/10.1111\/1759-7714.13226","journal-title":"Thorac Cancer"},{"key":"14_CR202","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.3390\/CANCERS13122962\/S1","volume":"13","author":"JP Melana","year":"2021","unstructured":"Melana JP, Mignolli F, Stoyanoff T et al (2021) The hypoxic microenvironment induces stearoyl-coa desaturase-1 overexpression and lipidomic profile changes in clear cell renal cell carcinoma. Cancers (Basel) 13:2962. https:\/\/doi.org\/10.3390\/CANCERS13122962\/S1","journal-title":"Cancers (Basel)"},{"key":"14_CR203","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/S13046-019-1164-5","volume":"38","author":"L Mele","year":"2019","unstructured":"Mele L, La Noce M, Paino F et al (2019) Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation. J Exp Clin Cancer Res 38:160. https:\/\/doi.org\/10.1186\/S13046-019-1164-5","journal-title":"J Exp Clin Cancer Res"},{"key":"14_CR204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox8120603","volume":"8","author":"C Mendes","year":"2019","unstructured":"Mendes C, Serpa J (2019) Metabolic remodelling: an accomplice for new therapeutic strategies to fight lung cancer. Antioxidants 8:1\u201325. https:\/\/doi.org\/10.3390\/antiox8120603","journal-title":"Antioxidants"},{"key":"14_CR205","doi-asserted-by":"publisher","first-page":"20240752","DOI":"10.1042\/BSR20240752\/234693","volume":"44","author":"C Mendes","year":"2024","unstructured":"Mendes C, Lemos I, Hip\u00f3lito A et al (2024) Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells. Biosci Rep 44:20240752. https:\/\/doi.org\/10.1042\/BSR20240752\/234693","journal-title":"Biosci Rep"},{"key":"14_CR206","doi-asserted-by":"publisher","first-page":"118405","DOI":"10.1016\/J.BIOPHA.2025.118405","volume":"190","author":"C Mendes","year":"2025","unstructured":"Mendes C, Martins F, Granja S et al (2025) Metabolism-targeted therapy in NSCLC\u2014a new theranostics inhalation approach using lactate functionalized and selenium-chrysin loaded nanoparticles (SeChry@PUREG4-LA24. Biomed Pharmacother 190:118405. https:\/\/doi.org\/10.1016\/J.BIOPHA.2025.118405","journal-title":"Biomed Pharmacother"},{"key":"14_CR207","doi-asserted-by":"publisher","unstructured":"Mendes C, Lemos I, Francisco I et al (2023) NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC. Lung Cancer 182:1-21. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107283","DOI":"10.1016\/j.lungcan.2023.107283"},{"key":"14_CR208","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.1158\/0008-5472.CAN-08-1235","volume":"68","author":"T Migita","year":"2008","unstructured":"Migita T, Narita T, Nomura K et al (2008) ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 68:8547\u20138554. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1235","journal-title":"Cancer Res"},{"key":"14_CR209","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"key":"14_CR210","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/DISEASES12050093","volume":"12","author":"P Mohanty","year":"2024","unstructured":"Mohanty P, Pande B, Acharya R et al (2024) Unravelling the triad of lung cancer, drug resistance, and metabolic pathways. Diseases 12:93. https:\/\/doi.org\/10.3390\/DISEASES12050093","journal-title":"Diseases"},{"key":"14_CR211","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947\u2013957. https:\/\/doi.org\/10.1056\/NEJMoa0810699","journal-title":"N Engl J Med"},{"key":"14_CR212","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMOA1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629\u2013640. https:\/\/doi.org\/10.1056\/NEJMOA1612674","journal-title":"N Engl J Med"},{"key":"14_CR213","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819\u20131830. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"14_CR214","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.celrep.2016.12.061","volume":"18","author":"M Momcilovic","year":"2017","unstructured":"Momcilovic M, Bailey ST, Lee JT et al (2017) Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer. Cell Rep 18:601\u2013610. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.061","journal-title":"Cell Rep"},{"key":"14_CR215","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/IJC.31868","volume":"144","author":"S Mondal","year":"2019","unstructured":"Mondal S, Roy D, Sarkar Bhattacharya S et al (2019) Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. Int J Cancer 144:178\u2013189. https:\/\/doi.org\/10.1002\/IJC.31868","journal-title":"Int J Cancer"},{"key":"14_CR216","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.athoracsur.2012.12.037","volume":"95","author":"P Mordant","year":"2013","unstructured":"Mordant P, Grand B, Cazes A et al (2013) Adenosquamous carcinoma of the lung: surgical management, pathologic characteristics, and prognostic implications. Ann Thorac Surg 95:1189\u20131195. https:\/\/doi.org\/10.1016\/j.athoracsur.2012.12.037","journal-title":"Ann Thorac Surg"},{"key":"14_CR217","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/JTO.0B013E3181C5920C","volume":"5","author":"D Morgensztern","year":"2010","unstructured":"Morgensztern D, Ng SH, Gao F, Govindan R (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5:29\u201333. https:\/\/doi.org\/10.1097\/JTO.0B013E3181C5920C","journal-title":"J Thorac Oncol"},{"key":"14_CR218","doi-asserted-by":"publisher","first-page":"12452","DOI":"10.1073\/pnas.1818521116","volume":"116","author":"M Morotti","year":"2019","unstructured":"Morotti M, Bridges E, Valli A et al (2019) Hypoxia-induced switch in SNAT2\/SLC38A2 regulation generates endocrine resistance in breast cancer. Proc Natl Acad Sci USA 116:12452\u201312461. https:\/\/doi.org\/10.1073\/pnas.1818521116","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR219","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/BIOM11020141","volume":"11","author":"R Mosaoa","year":"2021","unstructured":"Mosaoa R, Kasprzyk-Pawelec A, Fernandez HR, Avantaggiati ML (2021) The mitochondrial citrate carrier SLC25A1\/CIC and the fundamental role of citrate in cancer, inflammation and beyond. Biomolecules 11:141. https:\/\/doi.org\/10.3390\/BIOM11020141","journal-title":"Biomolecules"},{"key":"14_CR220","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/S12185-012-1070-5","volume":"95","author":"V Mucaj","year":"2012","unstructured":"Mucaj V, Shay JES, Simon MC (2012) Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol 95:464\u2013470. https:\/\/doi.org\/10.1007\/S12185-012-1070-5","journal-title":"Int J Hematol"},{"key":"14_CR221","doi-asserted-by":"publisher","unstructured":"Ni T, He Z, Dai Y et al (2017) Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1\u03b1-modulated fatty acid metabolism. Cell Death Dis 8:1-12. https:\/\/doi.org\/10.1038\/cddis.2017.261","DOI":"10.1038\/cddis.2017.261"},{"key":"14_CR222","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3390\/CANCERS15092472\/S1","volume":"15","author":"H Nisar","year":"2023","unstructured":"Nisar H, Sanchidri\u00e1n Gonz\u00e1lez PM, Brauny M et al (2023) Hypoxia changes energy metabolism and growth rate in non-small cell lung cancer cells. Cancers (Basel) 15:2472. https:\/\/doi.org\/10.3390\/CANCERS15092472\/S1","journal-title":"Cancers (Basel)"},{"key":"14_CR223","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/IJC.32193","volume":"146","author":"M Nurmik","year":"2020","unstructured":"Nurmik M, Ullmann P, Rodriguez F et al (2020) In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer 146:895\u2013905. https:\/\/doi.org\/10.1002\/IJC.32193","journal-title":"Int J Cancer"},{"key":"14_CR224","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/S11010-017-2977-1","volume":"431","author":"S Ohnami","year":"2017","unstructured":"Ohnami S, Ohshima K, Nagashima T et al (2017) Comprehensive characterization of genes associated with the TP53 signal transduction pathway in various tumors. Mol Cell Biochem 431:75\u201385. https:\/\/doi.org\/10.1007\/S11010-017-2977-1","journal-title":"Mol Cell Biochem"},{"key":"14_CR225","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655. https:\/\/doi.org\/10.1097\/00000421-198212000-00014","journal-title":"Am J Clin Oncol"},{"key":"14_CR226","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/OP.24.00177","volume":"20","author":"DH Owen","year":"2024","unstructured":"Owen DH, Jaiyesimi IA, Leighl NB et al (2024) Therapy for stage IV non\u2013small cell lung cancer with and without driver alterations: ASCO Living Guideline Clinical Insights. JCO Oncol Pract 20:893\u2013898. https:\/\/doi.org\/10.1200\/OP.24.00177","journal-title":"JCO Oncol Pract"},{"key":"14_CR227","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (1979) 304:1497\u20131500. https:\/\/doi.org\/10.1126\/science.1099314","journal-title":"Science (1979)"},{"key":"14_CR228","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/IJMS21010234","volume":"21","author":"B Pajak","year":"2019","unstructured":"Pajak B, Siwiak E, So\u0142tyka M et al (2019) 2-Deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci 21:234. https:\/\/doi.org\/10.3390\/IJMS21010234","journal-title":"Int J Mol Sci"},{"key":"14_CR229","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3389\/FPHAR.2019.00590\/BIBTEX","volume":"10","author":"Y Pan","year":"2019","unstructured":"Pan Y, Zheng Q, Ni W et al (2019) Breaking glucose transporter 1\/pyruvate kinase M2 glycolytic loop is required for cantharidin inhibition of metastasis in highly metastatic breast cancer. Front Pharmacol 10:590. https:\/\/doi.org\/10.3389\/FPHAR.2019.00590\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"14_CR230","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/PNAS.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306\u201313311. https:\/\/doi.org\/10.1073\/PNAS.0405220101","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR231","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2006.01.012","volume":"3","author":"I Papandreou","year":"2006","unstructured":"Papandreou I, Cairns RA, Fontana L et al (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187\u2013197. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.012","journal-title":"Cell Metab"},{"key":"14_CR232","doi-asserted-by":"publisher","first-page":"e000706","DOI":"10.1136\/ESMOOPEN-2020-000706","volume":"5","author":"S Papillon-Cavanagh","year":"2020","unstructured":"Papillon-Cavanagh S, Doshi P, Dobrin R et al (2020) STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open 5:e000706. https:\/\/doi.org\/10.1136\/ESMOOPEN-2020-000706","journal-title":"ESMO Open"},{"key":"14_CR233","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3390\/CELLS9102308","volume":"9","author":"JH Park","year":"2020","unstructured":"Park JH, Pyun WY, Park HH (2020) Cancer metabolism: phenotype, signaling and therapeutic targets. Cells 9:2308. https:\/\/doi.org\/10.3390\/CELLS9102308","journal-title":"Cells"},{"key":"14_CR234","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/1535-7163.MCT-13-0026","volume":"12","author":"KM Parnell","year":"2013","unstructured":"Parnell KM, Foulks JM, Nix RN et al (2013) Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol Cancer Ther 12:1453\u20131460. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0026","journal-title":"Mol Cancer Ther"},{"key":"14_CR235","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","volume":"40","author":"A Passaro","year":"2022","unstructured":"Passaro A, Brahmer J, Antonia S et al (2022) Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J Clin Oncol 40:598\u2013610. https:\/\/doi.org\/10.1200\/JCO.21.01845","journal-title":"J Clin Oncol"},{"key":"14_CR236","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","volume":"24","author":"KC Patra","year":"2013","unstructured":"Patra KC, Wang Q, Bhaskar PT et al (2013) Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24:213\u2013228. https:\/\/doi.org\/10.1016\/j.ccr.2013.06.014","journal-title":"Cancer Cell"},{"key":"14_CR237","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23:27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006","journal-title":"Cell Metab"},{"key":"14_CR238","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/J.MOLMET.2019.07.006","volume":"33","author":"VL Payen","year":"2020","unstructured":"Payen VL, Mina E, Van H\u00e9e VF et al (2020) Monocarboxylate transporters in cancer. Mol Metab\u200933:48\u201366.\u2009https:\/\/doi.org\/10.1016\/J.MOLMET.2019.07.006","journal-title":"Mol Metab"},{"key":"14_CR239","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ANNONC\/MDW611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares L, Tan EH, O\u2019Byrne K et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28:270\u2013277. https:\/\/doi.org\/10.1093\/ANNONC\/MDW611","journal-title":"Ann Oncol"},{"key":"14_CR240","doi-asserted-by":"publisher","first-page":"31363","DOI":"10.31083\/FBL31363\/PDF","volume":"30","author":"BP Peixoto","year":"2025","unstructured":"Peixoto BP, Clague RA, Reddy JP, Wettersten HI (2025) The Emerging Roles of Metabolic Reprogramming in Non-Small Cell Lung Cancer Progression. Front Biosci (Landmark Ed) 30:31363. https:\/\/doi.org\/10.31083\/FBL31363\/PDF","journal-title":"Front Biosci (Landmark Ed)"},{"key":"14_CR241","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/J.CMET.2024.04.018","volume":"36","author":"F Peng","year":"2024","unstructured":"Peng F, Lu J, Su K et al (2024) Oncogenic fatty acid oxidation senses circadian disruption in sleep-deficiency-enhanced tumorigenesis. Cell Metab 36:1598\u20131618. e11. https:\/\/doi.org\/10.1016\/J.CMET.2024.04.018 e11.","journal-title":"Cell Metab"},{"key":"14_CR242","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552\u20133559. https:\/\/doi.org\/10.1200\/JCO.2007.13.9030","journal-title":"J Clin Oncol"},{"key":"14_CR243","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/CNCR.31043","volume":"124","author":"RN Pillai","year":"2018","unstructured":"Pillai RN, Behera M, Owonikoko TK et al (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124:271\u2013277. https:\/\/doi.org\/10.1002\/CNCR.31043","journal-title":"Cancer"},{"key":"14_CR244","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1002\/CNCR.28326","volume":"119","author":"PF Pinsky","year":"2013","unstructured":"Pinsky PF, Church TR, Izmirlian G, Kramer BS (2013) The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 119:3976\u20133983. https:\/\/doi.org\/10.1002\/CNCR.28326","journal-title":"Cancer"},{"key":"14_CR245","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","volume":"8","author":"Z Piotrowska","year":"2018","unstructured":"Piotrowska Z, Isozaki H, Lennerz JK et al (2018) Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov 8:1529\u20131539. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1022","journal-title":"Cancer Discov"},{"key":"14_CR246","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/1078-0432.CCR-13-2270","volume":"20","author":"R Polanski","year":"2014","unstructured":"Polanski R, Hodgkinson CL, Fusi A et al (2014) Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res 20:926\u2013937. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2270","journal-title":"Clin Cancer Res"},{"key":"14_CR247","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10350","volume":"476","author":"R Possemato","year":"2011","unstructured":"Possemato R, Marks KM, Shaul YD et al (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476:346\u2013350. https:\/\/doi.org\/10.1038\/nature10350","journal-title":"Nature"},{"key":"14_CR248","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040820","volume":"13","author":"MG Raso","year":"2021","unstructured":"Raso MG, Bota-Rabassedas N, Wistuba II (2021) Pathology and classification of SCLC. Cancers (Basel) 13:1\u201311. https:\/\/doi.org\/10.3390\/cancers13040820","journal-title":"Cancers (Basel)"},{"key":"14_CR249","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/J.CANLET.2007.07.021","volume":"257","author":"S Rastogi","year":"2007","unstructured":"Rastogi S, Banerjee S, Chellappan S, Simon GR (2007) Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 257:244\u2013251. https:\/\/doi.org\/10.1016\/J.CANLET.2007.07.021","journal-title":"Cancer Lett"},{"key":"14_CR250","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3389\/FIMMU.2019.01878","volume":"10","author":"D Raychaudhuri","year":"2019","unstructured":"Raychaudhuri D, Bhattacharya R, Sinha BP et al (2019) Lactate induces pro-tumor reprogramming in intratumoral plasmacytoid dendritic cells. Front Immunol 10:1878. https:\/\/doi.org\/10.3389\/FIMMU.2019.01878","journal-title":"Front Immunol"},{"key":"14_CR251","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","volume":"7","author":"M Reck","year":"2019","unstructured":"Reck M, Mok TS, Nishio M et al (2019) Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 7:387\u2013401. https:\/\/doi.org\/10.1016\/S2213-2600(19)30084-0","journal-title":"Lancet Respir Med"},{"key":"14_CR252","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.ESMOOP.2021.100273","volume":"6","author":"M Reck","year":"2021","unstructured":"Reck M, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open 6:1\u201313. https:\/\/doi.org\/10.1016\/J.ESMOOP.2021.100273","journal-title":"ESMO Open"},{"key":"14_CR253","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/MCO.0000000000000393","volume":"20","author":"JA Reisz","year":"2017","unstructured":"Reisz JA, D\u2019Alessandro A (2017) Measurement of metabolic fluxes using stable isotope tracers in whole animals and human patients. Curr Opin Clin Nutr Metab Care 20:366\u2013374. https:\/\/doi.org\/10.1097\/MCO.0000000000000393","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"14_CR254","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/JCO.23.00774","volume":"41","author":"GJ Riely","year":"2023","unstructured":"Riely GJ, Smit EF, Ahn MJ et al (2023) Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients with BRAF V600-mutant metastatic non-small-cell lung cancer. J Clin Oncol 41:3700\u20133711. https:\/\/doi.org\/10.1200\/JCO.23.00774","journal-title":"J Clin Oncol"},{"key":"14_CR255","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cllc.2020.10.006","volume":"22","author":"JW Riess","year":"2021","unstructured":"Riess JW, Frankel P, Shackelford D et al (2021) Phase 1 trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) inpatients with advanced NSCLC (NCI 10327): rationale and study design. Clin Lung Cancer 22:67\u201370. https:\/\/doi.org\/10.1016\/j.cllc.2020.10.006","journal-title":"Clin Lung Cancer"},{"key":"14_CR256","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","volume":"131","author":"K Rikova","year":"2007","unstructured":"Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190\u20131203. https:\/\/doi.org\/10.1016\/j.cell.2007.11.025","journal-title":"Cell"},{"key":"14_CR257","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"key":"14_CR258","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 28:1563. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0221","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"14_CR259","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","volume":"1","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Fisher DE, Garbe C et al (2015) Melanoma. Nat Rev Dis Primers 1:15003. https:\/\/doi.org\/10.1038\/nrdp.2015.3","journal-title":"Nat Rev Dis Primers"},{"key":"14_CR260","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3390\/CELLS10051056","volume":"10","author":"C Schiliro","year":"2021","unstructured":"Schiliro C, Firestein BL (2021) Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells 10:1056. https:\/\/doi.org\/10.3390\/CELLS10051056","journal-title":"Cells"},{"key":"14_CR261","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/J.BBCAN.2017.05.004","volume":"1868","author":"L Schito","year":"2017","unstructured":"Schito L, Rey S (2017) Hypoxic pathobiology of breast cancer metastasis. Biochim Biophys Acta 1868:239\u2013245. https:\/\/doi.org\/10.1016\/J.BBCAN.2017.05.004","journal-title":"Biochim Biophys Acta"},{"key":"14_CR262","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","volume":"31","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Rizvi H, Bandlamudi C et al (2020) Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol 31:599\u2013608. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.065","journal-title":"Ann Oncol"},{"key":"14_CR263","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.3390\/IJMS23137222","volume":"23","author":"M de Scordilli","year":"2022","unstructured":"de Scordilli M, Michelotti A, Bertoli E et al (2022) Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: current evidence and ongoing trials. Int J Mol Sci 23:7222. https:\/\/doi.org\/10.3390\/IJMS23137222","journal-title":"Int J Mol Sci"},{"key":"14_CR264","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/J.JCONREL.2018.02.020","volume":"275","author":"K Seidi","year":"2018","unstructured":"Seidi K, Neubauer HA, Moriggl R et al (2018) Tumor target amplification: implications for nano drug delivery systems. J Controlled Release 275:142\u2013161. https:\/\/doi.org\/10.1016\/J.JCONREL.2018.02.020","journal-title":"J Controlled Release"},{"key":"14_CR265","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI72873","volume":"125","author":"K Sellers","year":"2015","unstructured":"Sellers K, Fox MP, Ii MB et al (2015) Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J Clin Invest 125:687\u2013698. https:\/\/doi.org\/10.1172\/JCI72873","journal-title":"J Clin Invest"},{"key":"14_CR266","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/J.GDE.2009.10.009","volume":"20","author":"GL Semenza","year":"2010","unstructured":"Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51\u201356. https:\/\/doi.org\/10.1016\/J.GDE.2009.10.009","journal-title":"Curr Opin Genet Dev"},{"key":"14_CR267","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/SCITRANSLMED.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3002003","journal-title":"Sci Transl Med"},{"key":"14_CR268","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4161\/CC.10.2.14476","volume":"10","author":"J Serpa","year":"2011","unstructured":"Serpa J, Dias S (2011) Metabolic cues from the microenvironment act as a major selective factor for cancer progression and metastases formation. Cell Cycle 10:180\u2013181. https:\/\/doi.org\/10.4161\/CC.10.2.14476","journal-title":"Cell Cycle"},{"key":"14_CR269","doi-asserted-by":"publisher","unstructured":"Serpa J (2020) Metabolic remodeling as a way of adapting to tumor microenvironment (TME), a job of several holders. Adv Exp Med Biol 1219:1\u201334. https:\/\/doi.org\/10.1007\/978-3-030-34025-4_1","DOI":"10.1007\/978-3-030-34025-4_1"},{"key":"14_CR270","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J\u00a0Clin Oncol 27:4247\u20134253. https:\/\/doi.org\/10.1200\/JCO.2009.22.6993","journal-title":"J Clin Oncol"},{"key":"14_CR271","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Felip E, Bauer TM et al (2017) Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 18:1590\u20131599. https:\/\/doi.org\/10.1016\/S1470-2045(17)30680-0","journal-title":"Lancet Oncol"},{"key":"14_CR272","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/S13402-020-00508-6","volume":"43","author":"J Shen","year":"2020","unstructured":"Shen J, Jin Z, Lv H et al (2020) PFKP is highly expressed in lung cancer and regulates glucose metabolism. Cell Oncol 43:617\u2013629. https:\/\/doi.org\/10.1007\/S13402-020-00508-6","journal-title":"Cell Oncol"},{"key":"14_CR273","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"F Shepherd","year":"2005","unstructured":"Shepherd F, Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non\u2013small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"14_CR274","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/MCO2.6","volume":"1","author":"R Shi","year":"2020","unstructured":"Shi R, Tang YQ, Miao H (2020) Metabolism in tumor microenvironment: implications for cancer immunotherapy. MedComm (Beijing) 1:47\u201368. https:\/\/doi.org\/10.1002\/MCO2.6","journal-title":"MedComm (Beijing)"},{"key":"14_CR275","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/fampra\/cmt076","volume":"31","author":"J Shim","year":"2014","unstructured":"Shim J, Brindle L, Simon M, George S (2014) A systematic review of symptomatic diagnosis of lung cancer. Fam Pract 31:137\u2013148. https:\/\/doi.org\/10.1093\/fampra\/cmt076","journal-title":"Fam Pract"},{"key":"14_CR276","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"14_CR277","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"14_CR278","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/1078-0432.CCR-20-1985","volume":"27","author":"A Singh","year":"2021","unstructured":"Singh A, Daemen A, Nickles D et al (2021) NRF2 Activation promotes aggressive lung cancer and associates with poor clinical outcomes. Clin Cancer Res 27:877\u2013888. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1985","journal-title":"Clin Cancer Res"},{"key":"14_CR279","doi-asserted-by":"publisher","unstructured":"Singh B, Patwardhan RS, Jayakumar S et al (2020) Oxidative stress associated metabolic adaptations regulate radioresistance in human lung cancer cells. J\u00a0Photochem Photobiol B 213:1-9. https:\/\/doi.org\/10.1016\/j.jphotobiol.2020.112080","DOI":"10.1016\/j.jphotobiol.2020.112080"},{"key":"14_CR280","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3390\/PHARMACEUTICS15082090","volume":"15","author":"Z Sirhan","year":"2023","unstructured":"Sirhan Z, Alojair R, Thyagarajan A, Sahu RP (2023) Therapeutic implications of PTEN in non-small cell lung cancer. Pharmaceutics 15:2090. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15082090","journal-title":"Pharmaceutics"},{"key":"14_CR281","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/1078-0432.CCR-20-2859","volume":"27","author":"P Sitthideatphaiboon","year":"2021","unstructured":"Sitthideatphaiboon P, Galan-Cobo A, Negrao MV et al (2021) STK11\/LKB1 mutations in NSCLC are associated with KEAP1\/NRF2-dependent radiotherapy resistance targetable by glutaminase inhibition. Clin Cancer Res 27:1720\u20131733. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2859","journal-title":"Clin Cancer Res"},{"key":"14_CR282","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","volume":"635","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis F, Araujo HA, Do MT et al (2024) CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors. Nature 635:462\u2013471. https:\/\/doi.org\/10.1038\/s41586-024-07943-7","journal-title":"Nature"},{"key":"14_CR283","first-page":"1178","volume":"8","author":"J-C Soria","year":"2002","unstructured":"Soria J-C, Lee H-Y, Lee JI et al (2002) Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8:1178\u20131184","journal-title":"Clin Cancer Res"},{"key":"14_CR284","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMOA1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMOA1713137","journal-title":"N Engl J Med"},{"key":"14_CR285","doi-asserted-by":"publisher","first-page":"v915","DOI":"10.1093\/annonc\/mdz293","volume":"30","author":"D Spigel","year":"2019","unstructured":"Spigel D, de Marinis F, Giaccone G et al (2019) IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1\u2013selected NSCLC. Ann Oncol 30:v915. https:\/\/doi.org\/10.1093\/annonc\/mdz293","journal-title":"Ann Oncol"},{"key":"14_CR286","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","volume":"172","author":"S Su","year":"2018","unstructured":"Su S, Chen J, Yao H et al (2018) CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 172:841\u2013856. e16. https:\/\/doi.org\/10.1016\/j.cell.2018.01.009","journal-title":"Cell"},{"key":"14_CR287","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1172\/JCI69589","volume":"123","author":"M Sukumar","year":"2013","unstructured":"Sukumar M, Liu J, Ji Y et al (2013) Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 123:4479\u20134488. https:\/\/doi.org\/10.1172\/JCI69589","journal-title":"J Clin Invest"},{"key":"14_CR288","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C et al (2023) Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther 8:1\u201326. https:\/\/doi.org\/10.1038\/s41392-023-01522-4","journal-title":"Signal Transduct Target Ther"},{"key":"14_CR289","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cmet.2013.11.022","volume":"19","author":"RC Sun","year":"2014","unstructured":"Sun RC, Denko NC (2014) Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab 19:285\u2013292. https:\/\/doi.org\/10.1016\/j.cmet.2013.11.022","journal-title":"Cell Metab"},{"key":"14_CR290","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nrc2190","volume":"7","author":"S Sun","year":"2007","unstructured":"Sun S, Schiller JH, Gazdar AF (2007) Lung cancer in never smokers\u2014a different disease. Nat Rev Cancer 7:778\u2013790. https:\/\/doi.org\/10.1038\/nrc2190","journal-title":"Nat Rev Cancer"},{"key":"14_CR291","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/CAAC.21660","journal-title":"CA Cancer J Clin"},{"key":"14_CR292","doi-asserted-by":"publisher","first-page":"e0217131","DOI":"10.1371\/JOURNAL.PONE.0217131","volume":"14","author":"A Suzuki","year":"2019","unstructured":"Suzuki A, Puri S, Leland P et al (2019) Subcellular compartmentalization of PKM2 identifies anti-PKM2 therapy response in vitro and in vivo mouse model of human non-small-cell lung cancer. PLoS ONE 14:e0217131. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0217131","journal-title":"PLoS ONE"},{"key":"14_CR293","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/JTO.0b013e318287c91e","volume":"8","author":"AL Tam","year":"2013","unstructured":"Tam AL, Kim ES, Lee JJ et al (2013) Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol 8:436\u2013442. https:\/\/doi.org\/10.1097\/JTO.0b013e318287c91e","journal-title":"J Thorac Oncol"},{"key":"14_CR294","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12943-018-0778-0","volume":"17","author":"CS Tan","year":"2018","unstructured":"Tan CS, Kumarakulasinghe NB, Huang YQ et al (2018) Third generation EGFR TKIs: current data and future directions. Mol Cancer 17:1\u201314. https:\/\/doi.org\/10.1186\/S12943-018-0778-0","journal-title":"Mol Cancer"},{"key":"14_CR295","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.2174\/0929867324666170203121449","volume":"24","author":"W Tan","year":"2017","unstructured":"Tan W, Zhong Z, Wang S et al (2017a) The typical metabolic modifiers conferring improvement in cancer resistance. Curr Med Chem 24:3698\u20133710. https:\/\/doi.org\/10.2174\/0929867324666170203121449","journal-title":"Curr Med Chem"},{"key":"14_CR296","doi-asserted-by":"publisher","first-page":"60954","DOI":"10.18632\/ONCOTARGET.17604","volume":"8","author":"Z Tan","year":"2017","unstructured":"Tan Z, Yang C, Zhang X et al (2017b) Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients. Oncotarget 8:60954. https:\/\/doi.org\/10.18632\/ONCOTARGET.17604","journal-title":"Oncotarget"},{"key":"14_CR297","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.lungcan.2005.10.003","volume":"51","author":"JM Tang","year":"2006","unstructured":"Tang JM, He QY, Guo RX, Chang XJ (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51:181\u2013191. https:\/\/doi.org\/10.1016\/j.lungcan.2005.10.003","journal-title":"Lung Cancer"},{"key":"14_CR298","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K et al. (2021) Epidemiology of lung cancer. Contemp Oncol 25:45. https:\/\/doi.org\/10.5114\/wo.2021.103829","journal-title":"Contemp Oncol"},{"key":"14_CR299","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"The National Lung Screening Trial Research Team","year":"2011","unstructured":"The National Lung Screening Trial Research Team (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395\u2013409. https:\/\/doi.org\/10.1056\/NEJMoa1102873","journal-title":"N Engl J Med"},{"key":"14_CR300","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/S00018-019-03039-Y","volume":"76","author":"LW Thomas","year":"2019","unstructured":"Thomas LW, Ashcroft M (2019) Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. Cell Mol Life Sci 76:1759\u20131777. https:\/\/doi.org\/10.1007\/S00018-019-03039-Y","journal-title":"Cell Mol Life Sci"},{"key":"14_CR301","doi-asserted-by":"publisher","unstructured":"Thress KS, Paweletz CP, Felip E et al (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21:560\u2013562. https:\/\/doi.org\/10.1038\/nm.3854","DOI":"10.1038\/nm.3854"},{"key":"14_CR302","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/0008-5472.CAN-05-2625","volume":"66","author":"S Toyooka","year":"2006","unstructured":"Toyooka S, Tokumo M, Shigematsu H et al (2006) Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66:1371\u20131375. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2625","journal-title":"Cancer Res"},{"key":"14_CR303","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.2012.46.9270","volume":"31","author":"WD Travis","year":"2013","unstructured":"Travis WD, Brambilla E, Riely GJ (2013) New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 31:992\u20131001. https:\/\/doi.org\/10.1200\/JCO.2012.46.9270","journal-title":"J Clin Oncol"},{"key":"14_CR304","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J\u00a0Thorac Oncol 10:1243\u20131260. https:\/\/doi.org\/10.1097\/JTO.0000000000000630","journal-title":"J Thorac Oncol"},{"key":"14_CR305","unstructured":"Travis WD, Brambilla E, Burke AP, Marx ANA (2015) WHO classification of tumours of the lung, pleura, thymus and heart, 4th edn. International Agency for Research on Cancer, Lyon"},{"key":"14_CR306","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12630-x","volume":"7","author":"DJ Urban","year":"2017","unstructured":"Urban DJ, Martinez NJ, Davis MI et al (2017) Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays. Sci Rep 7:12758. https:\/\/doi.org\/10.1038\/s41598-017-12630-x","journal-title":"Sci Rep"},{"key":"14_CR307","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3389\/FONC.2019.01215","volume":"9","author":"K Vanhove","year":"2019","unstructured":"Vanhove K, Graulus GJ, Mesotten L et al (2019) The metabolic landscape of lung cancer: new insights in a disturbed glucose metabolism. Front Oncol 9:1215. https:\/\/doi.org\/10.3389\/FONC.2019.01215","journal-title":"Front Oncol"},{"key":"14_CR308","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G De Velasco","year":"2017","unstructured":"De Velasco G, Je Y, Boss\u00e9 D et al (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5:312\u2013318. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0237","journal-title":"Cancer Immunol Res"},{"key":"14_CR309","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1158\/0008-5472.CAN-12-1097","volume":"72","author":"S Vicent","year":"2012","unstructured":"Vicent S, Sayles LC, Vaka D et al (2012) Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res 72:5744\u20135756. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1097","journal-title":"Cancer Res"},{"key":"14_CR310","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.7150\/THNO.51797","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Zhao C, Xu F et al (2021) Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics 11:2875. https:\/\/doi.org\/10.7150\/THNO.51797","journal-title":"Theranostics"},{"key":"14_CR311","doi-asserted-by":"publisher","DOI":"10.1186\/S12935-016-0280-Y","volume":"16","author":"H Wang","year":"2016","unstructured":"Wang H, Wang L, Zhang Y et al (2016a) Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int 16:9. https:\/\/doi.org\/10.1186\/S12935-016-0280-Y","journal-title":"Cancer Cell Int"},{"key":"14_CR312","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1515\/MED-2016-0014","volume":"11","author":"Y Wang","year":"2016","unstructured":"Wang Y, Guo Z, Li Y, Zhou Q (2016b) Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. Open Med 11:68\u201377. https:\/\/doi.org\/10.1515\/MED-2016-0014","journal-title":"Open Med"},{"key":"14_CR313","doi-asserted-by":"publisher","first-page":"1200538","DOI":"10.3389\/FPHAR.2023.1200538","volume":"14","author":"K Wang","year":"2023","unstructured":"Wang K, Lu H, Wang X et al (2023) Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC. Front Pharmacol 14:1200538. https:\/\/doi.org\/10.3389\/FPHAR.2023.1200538","journal-title":"Front Pharmacol"},{"key":"14_CR314","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924\u2013937. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6","journal-title":"Lancet Oncol"},{"key":"14_CR315","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904\u20135912. https:\/\/doi.org\/10.1038\/onc.2008.271","journal-title":"Oncogene"},{"key":"14_CR316","doi-asserted-by":"publisher","first-page":"108444","DOI":"10.1016\/j.celrep.2020.108444","volume":"33","author":"CA Wohlhieter","year":"2020","unstructured":"Wohlhieter CA, Richards AL, Uddin F et al (2020) Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer. Cell Rep 33:108444. https:\/\/doi.org\/10.1016\/j.celrep.2020.108444","journal-title":"Cell Rep"},{"key":"14_CR317","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/J.ABB.2016.11.002","volume":"613","author":"M Wolff","year":"2017","unstructured":"Wolff M, Kosyna FK, Dunst J et al (2017) Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells. Arch Biochem Biophys 613:23\u201330. https:\/\/doi.org\/10.1016\/J.ABB.2016.11.002","journal-title":"Arch Biochem Biophys"},{"key":"14_CR318","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/IJC.34127","volume":"151","author":"KY Wong","year":"2022","unstructured":"Wong KY, Cheung AHK, Chen B et al (2022) Cancer-associated fibroblasts in nonsmall cell lung cancer: from molecular mechanisms to clinical implications. Int J Cancer 151:1195\u20131215. https:\/\/doi.org\/10.1002\/IJC.34127","journal-title":"Int J Cancer"},{"key":"14_CR319","doi-asserted-by":"publisher","unstructured":"Woodard GA, Jones KD, Jablons DM (2016) Lung cancer staging and prognosis. Cancer Treat Res Commun 170:47\u201375. https:\/\/doi.org\/10.1007\/978-3-319-40389-2_3","DOI":"10.1007\/978-3-319-40389-2_3"},{"key":"14_CR320","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yexcr.2017.02.014","volume":"352","author":"Q Wu","year":"2017","unstructured":"Wu Q, Yao B, Li N et al (2017a) Nrf2 mediates redox adaptation in NOX4-overexpressed non-small cell lung cancer cells. Exp Cell Res 352:245\u2013254. https:\/\/doi.org\/10.1016\/j.yexcr.2017.02.014","journal-title":"Exp Cell Res"},{"key":"14_CR321","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/J.BBRC.2015.03.071","volume":"460","author":"R Wu","year":"2015","unstructured":"Wu R, Galan-Acosta L, Norberg E (2015) Glucose metabolism provide distinct prosurvival benefits to non-small cell lung carcinomas. Biochem Biophys Res Commun 460:572\u2013577. https:\/\/doi.org\/10.1016\/J.BBRC.2015.03.071","journal-title":"Biochem Biophys Res Commun"},{"key":"14_CR322","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1002\/ijc.27779","volume":"132","author":"Y Wu","year":"2013","unstructured":"Wu Y, Li P, Zhang H et al (2013) Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography\/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer 132:E37\u2013E47. https:\/\/doi.org\/10.1002\/ijc.27779","journal-title":"Int J Cancer"},{"key":"14_CR323","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X et al (2017b) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18:1454\u20131466. https:\/\/doi.org\/10.1016\/S1470-2045(17)30608-3","journal-title":"Lancet Oncol"},{"key":"14_CR324","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-19-0507","volume":"8","author":"H Xiang","year":"2020","unstructured":"Xiang H, Ramil CP, Hai J et al (2020) Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma. Cancer Immunol Res 8:436\u2013450. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0507","journal-title":"Cancer Immunol Res"},{"key":"14_CR325","doi-asserted-by":"publisher","first-page":"57832","DOI":"10.18632\/ONCOTARGET.11068","volume":"7","author":"J Xiao","year":"2016","unstructured":"Xiao J, Hu C-P, He B-X et al (2016) PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature. Oncotarget 7:57832\u201357840. https:\/\/doi.org\/10.18632\/ONCOTARGET.11068","journal-title":"Oncotarget"},{"key":"14_CR326","doi-asserted-by":"publisher","first-page":"1037341","DOI":"10.3389\/FPHAR.2022.1037341","volume":"13","author":"JQ Xu","year":"2022","unstructured":"Xu JQ, Fu YL, Zhang J et al (2022) Targeting glycolysis in non-small cell lung cancer: promises and challenges. Front Pharmacol 13:1037341. https:\/\/doi.org\/10.3389\/FPHAR.2022.1037341","journal-title":"Front Pharmacol"},{"key":"14_CR327","doi-asserted-by":"publisher","first-page":"1238093","DOI":"10.3389\/FMOLB.2023.1238093","volume":"10","author":"X Yang","year":"2023","unstructured":"Yang X, Tang Z, Li J et al (2023) Progress of non-small-cell lung cancer with ROS1 rearrangement. Front Mol Biosci 10:1238093. https:\/\/doi.org\/10.3389\/FMOLB.2023.1238093","journal-title":"Front Mol Biosci"},{"key":"14_CR328","first-page":"5994","volume":"47","author":"G Yeh","year":"1987","unstructured":"Yeh G, Occhipinti S, Cowan K et al (1987) Adriamycin resistance in human tumor cells associated with marked alterations in the regulation of the hexose monophosphate shunt and its response to oxidant stress. Cancer Res 47:5994\u20135999","journal-title":"Cancer Res"},{"key":"14_CR329","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3349\/YMJ.2016.57.6.1312","volume":"57","author":"S Yuan","year":"2016","unstructured":"Yuan S, Qiao T, Zhuang X et al (2016) Knockdown of the M2 isoform of pyruvate kinase (PKM2) with shRNA enhances the effect of docetaxel in human NSCLC cell lines in vitro. Yonsei Med J 57:1312\u20131323. https:\/\/doi.org\/10.3349\/YMJ.2016.57.6.1312","journal-title":"Yonsei Med J"},{"key":"14_CR330","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5:288. https:\/\/doi.org\/10.21037\/tlcr.2016.06.07","journal-title":"Transl Lung Cancer Res"},{"key":"14_CR331","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","volume":"22","author":"HM Zarour","year":"2016","unstructured":"Zarour HM (2016) Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res 22:1856\u20131864. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1849","journal-title":"Clin Cancer Res"},{"key":"14_CR332","doi-asserted-by":"publisher","first-page":"113295","DOI":"10.1016\/j.celrep.2023.113295","volume":"42","author":"AM Zavitsanou","year":"2023","unstructured":"Zavitsanou AM, Pillai R, Hao Y et al (2023) KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell Rep 42:113295. https:\/\/doi.org\/10.1016\/j.celrep.2023.113295","journal-title":"Cell Rep"},{"key":"14_CR333","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/J.FREERADBIOMED.2016.10.500","volume":"101","author":"C Zeng","year":"2016","unstructured":"Zeng C, Wu Q, Wang J et al (2016) NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells. Free Radic Biol Med 101:236\u2013248. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2016.10.500","journal-title":"Free Radic Biol Med"},{"key":"14_CR334","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.18632\/ONCOTARGET.2025","volume":"5","author":"C Zhang","year":"2014","unstructured":"Zhang C, Lan T, Hou J et al (2014a) NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K\/Akt signaling. Oncotarget 5:4392\u20134405. https:\/\/doi.org\/10.18632\/ONCOTARGET.2025","journal-title":"Oncotarget"},{"key":"14_CR335","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/SCIENCE.1256930","volume":"346","author":"J Zhang","year":"2014","unstructured":"Zhang J, Fujimoto J, Zhang J et al (2014b) Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (1979)\u2009346:256\u2013259.\u2009https:\/\/doi.org\/10.1126\/SCIENCE.1256930","journal-title":"Science (1979)"},{"key":"14_CR336","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.celrep.2017.05.067","volume":"19","author":"B Zhang","year":"2017","unstructured":"Zhang B, Zheng A, Hydbring P et al (2017a) PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis. Cell Rep 19:2289\u20132303. https:\/\/doi.org\/10.1016\/j.celrep.2017.05.067","journal-title":"Cell Rep"},{"key":"14_CR337","doi-asserted-by":"publisher","DOI":"10.1186\/S12943-017-0704-X","volume":"16","author":"J Zhang","year":"2017","unstructured":"Zhang J, Song F, Zhao X et al (2017b) EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer. Mol Cancer 16: 127. https:\/\/doi.org\/10.1186\/S12943-017-0704-X","journal-title":"Mol Cancer"},{"key":"14_CR338","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/S13045-024-01600-2","volume":"17","author":"F Zhang","year":"2024","unstructured":"Zhang F, Ma Y, Li D et al (2024) Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution. J Hematol Oncol 17:80. https:\/\/doi.org\/10.1186\/S13045-024-01600-2","journal-title":"J Hematol Oncol"},{"key":"14_CR339","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28\u201339. https:\/\/doi.org\/10.1038\/nrc2559","journal-title":"Nat Rev Cancer"},{"key":"14_CR340","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2019.101116","volume":"22","author":"J Zhang","year":"2019","unstructured":"Zhang J, Li H, Wu Q et al (2019) Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS\/PI3K signaling-dependent various cytokine production to promote NSCLC growth. Redox Biol 22:1\u201314. https:\/\/doi.org\/10.1016\/j.redox.2019.101116","journal-title":"Redox Biol"},{"key":"14_CR341","doi-asserted-by":"publisher","first-page":"2004750","DOI":"10.1002\/SMLL.202004750","volume":"17","author":"J Zhang","year":"2021","unstructured":"Zhang J, Fu B, Li M, Mi S (2021) Secretome of activated fibroblasts induced by exosomes for the discovery of biomarkers in non-small cell lung cancer.\u2009Small\u200917:2004750.\u2009https:\/\/doi.org\/10.1002\/SMLL.202004750","journal-title":"Small"},{"key":"14_CR342","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cell.2011.11.050","volume":"148","author":"WC Zhang","year":"2012","unstructured":"Zhang WC, Ng SC, Yang H et al (2012) Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148:259\u2013272. https:\/\/doi.org\/10.1016\/j.cell.2011.11.050","journal-title":"Cell"},{"key":"14_CR343","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/cas.12108","volume":"104","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Wang H, Zhang J et al (2013) Positive feedback loop and synergistic effects between hypoxia-inducible factor-2\u03b1 and stearoyl-CoA desaturase-1 promote tumorigenesis in clear cell renal cell carcinoma. Cancer Sci 104:416\u2013422. https:\/\/doi.org\/10.1111\/cas.12108","journal-title":"Cancer Sci"},{"key":"14_CR344","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1016\/j.cllc.2025.03.007","volume":"26","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu Y, Ye G et al (2025) First report of NSCLC With IDH1 mutation: a case report. Clin Lung Cancer\u200926:e321\u2013e324.\u2009https:\/\/doi.org\/10.1016\/j.cllc.2025.03.007","journal-title":"Clin Lung Cancer"},{"key":"14_CR345","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-019-0156-8","volume":"5","author":"J Zhao","year":"2019","unstructured":"Zhao J, Ma Y, Zhang Y et al (2019) Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism. Cell Death Discov 5:1\u201313. https:\/\/doi.org\/10.1038\/s41420-019-0156-8","journal-title":"Cell Death Discov"},{"key":"14_CR346","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.2741\/3826","volume":"16","author":"Y Zhao","year":"2011","unstructured":"Zhao Y, Liu H, Riker AI et al (2011) Emerging metabolic targets in cancer therapy. Front Biosci 16:1860. https:\/\/doi.org\/10.2741\/3826","journal-title":"Front Biosci"},{"key":"14_CR347","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.soc.2016.02.003","volume":"25","author":"M Zheng","year":"2016","unstructured":"Zheng M (2016) Classification and pathology of lung cancer. Surg Oncol Clin N Am 25:447\u2013468. https:\/\/doi.org\/10.1016\/j.soc.2016.02.003","journal-title":"Surg Oncol Clin N Am"},{"key":"14_CR348","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735\u2013742. https:\/\/doi.org\/10.1016\/S1470-2045(11)70184-X","journal-title":"Lancet Oncol"},{"key":"14_CR349","doi-asserted-by":"publisher","first-page":"837","DOI":"10.7150\/IJBS.31749","volume":"15","author":"L Zhou","year":"2019","unstructured":"Zhou L, Li M, Yu X et al (2019) Repression of hexokinases II-mediated glycolysis contributes to piperlongumine-induced tumor suppression in non-small cell lung cancer cells. Int Js Biol Sci 15:837. https:\/\/doi.org\/10.7150\/IJBS.31749","journal-title":"Int Js Biol Sci"},{"key":"14_CR350","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3892\/ol.2023.13745","volume":"25","author":"L Zhou","year":"2023","unstructured":"Zhou L, Zhang Q, Zhan Y et al (2023) Role and therapeutic targeting of glutamine metabolism in non-small cell lung cancer (Review). Oncol Lett 25:159","journal-title":"Oncol Lett"},{"key":"14_CR351","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/CANCERS11091231","volume":"11","author":"W Zhou","year":"2019","unstructured":"Zhou W, Wahl DR (2019) Metabolic abnormalities in glioblastoma and metabolic strategies to overcome treatment resistance. Cancers (Basel) 11:1231. https:\/\/doi.org\/10.3390\/CANCERS11091231","journal-title":"Cancers (Basel)"},{"key":"14_CR352","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.21037\/jtd.2018.03.186","volume":"10","author":"L Zhu","year":"2018","unstructured":"Zhu L, Jiang L, Yang J et al (2018) Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes. J Thorac Dis 10:2397\u20132402. https:\/\/doi.org\/10.21037\/jtd.2018.03.186","journal-title":"J Thorac Dis"}],"container-title":["Advances in Experimental Medicine and Biology","Cancer Metabolic Remodeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-12166-0_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:02:58Z","timestamp":1783771378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-12166-0_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032121653","9783032121660"],"references-count":353,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-12166-0_14","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-032-12166-0","asserted-by":"object"}]},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"12 July 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}